Artemether_71963-77-4_DataSheet_MedChemExpress

合集下载

厄贝沙坦说明书(英文)

Product InformationAVAPRO® (irbesartan)NAME OF THE MEDICINEAustralian Approved NameIrbesartan.Irbesartan is 2-butyl-3-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-1,3-diazaspiro [4,4] non-1-en-4-one.Chemical StructureThe chemical structure of irbesartan isCAS number: 138402-11-6DESCRIPTIONIrbesartan is a white, to practically white, powder that is less than 0.1mg/mL soluble in water and slightly soluble in alcohol and methylene chloride.AVAPRO® (irbesartan) is a nonpeptide angiotensin II receptor (AT1 subtype) antagonist. It is available as 75, 150 or 300 mg film coated tablets for oral administration. The white, biconvex , oval-shaped tablets are marked with a heart on one side and on the other side 2871 (75mg) or 2872 (150mg) or 2873 (300mg). The inactive ingredients are: carnauba wax, croscarmellose sodium, hypromellose, lactose, macrogol 3000, magnesium stearate, microcrystalline cellulose, silicon dioxide, and titanium dioxide.PHARMACOLOGYPharmacodynamicsIrbesartan is a specific antagonist of angiotensin II receptors (AT1 subtype). Angiotensin II is an important component of the renin-angiotensin system and is involved in the pathophysiology of hypertension and in sodium homeostasis. Irbesartan does not require metabolic activation for its activity.Irbesartan blocks the potent vasoconstrictor and aldosterone-secreting effects of angiotensin II by selective antagonism of the angiotensin II (AT1 subtype) receptors localized on vascular smooth muscle cells and in the adrenal cortex. It has no agonist activity at the AT1 receptor and a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor (a receptor that has not been shown to be associated with cardiovascular homeostasis).Irbesartan does not inhibit enzymes involved in the renin-angiotensin system (i.e., renin, angiotensin converting enzyme [ACE]) or affect other hormone receptors or ion channels involved in the cardiovascular regulation of blood pressure and sodium homeostasis.In healthy subjects, single oral irbesartan doses of up to 300mg produced dose-dependent inhibition of the pressor effect of angiotensin II infusions. Inhibition was complete (≥90%) at the time of peak irbesartan concentrations and sustained for 24 hours (60% and 40% at300mg and 150mg, respectively).In hypertensive patients, angiotensin II receptor inhibition following chronic administration of irbesartan causes a 1.5-2 fold rise in angiotensin II plasma concentration and a 2-3 fold increase in plasma renin levels. Aldosterone plasma concentrations generally decline following irbesartan administration, however serum potassium levels are not significantly affected at recommended doses.In hypertensive patients, chronic oral doses of irbesartan (up to 300mg) had no effect on glomerular filtration rate, renal plasma/blood flow or filtration fraction. In multiple dose studies in hypertensive patients, there were no notable effects on fasting triglycerides, total cholesterol or HDL-cholesterol or fasting glucose concentrations. There was no effect on serum uric acid during chronic oral administration. Following repeated doses of irbesartan, there was no uricosuric effect.PharmacokineticsIrbesartan is an orally active agent and does not require biotransformation for its activity. AbsorptionFollowing oral administration, irbesartan is rapidly and well absorbed. In studies employing an injection and an oral solution containing radio-labelled irbesartan the average absolute oral bioavailability of irbesartan was 60- 80%. Median peak plasma concentrations generally occurred 1.5 -2 hours after oral administration of irbesartan capsules and tablets. Food did not affect the bioavailability.DistributionIrbesartan is 90% protein-bound in the plasma, and has negligible binding to cellular components of blood. The volume of distribution (V ss) is 53-93 Litres.MetabolismFollowing oral or intravenous administration of 14C irbesartan more than 80% of the circulating plasma radioactivity was attributable to unchanged irbesartan. Irbesartan is metabolised by the liver via glucuronide conjugation and oxidation. The major circulating metabolite is irbesartan glucuronide (∼6%). Irbesartan undergoes oxidation primarily by thecytochrome P450 isoenzyme CYP2C9; isoenzyme CYP3A4 has negligible effect. It is not metabolised by, nor does it substantially induce or inhibit most isoenzymes commonly associated with drug metabolism (i.e., CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2D6, or CYP2E1). Irbesartan does not induce nor inhibit isoenzyme CYP3A4.ExcretionIrbesartan and its metabolites are excreted by both biliary and renal routes. About 20% of the administered radioactivity after an oral or intravenous dose of 14C irbesartan was recovered in urine with the remainder in the faeces. Less than 2% of the dose was excreted in urine as unchanged irbesartan.The terminal elimination half-life (t½) of irbesartan averaged 11 - 15 hours over a range ofirbesartan was 157 -176 mL/min, of which 3.0-3.5 mL/min was renal clearance. Irbesartan exhibits linear pharmacokinetics over the therapeutic dose range. Steady-state plasma concentrations are attained within 3 days after initiation of a once-daily dosing regimen. Limited accumulation (<20%) is observed in plasma upon repeated once-daily dosing.Special PopulationsIn male and female hypertensive subjects, higher (11-44%) plasma concentrations of irbesartan were observed in females than in males, although, following multiple dosing, males and females did not show differences in either accumulation or elimination half-life. No gender-specific differences in clinical effect have been observed.In elderly (male and female) normotensive subjects (65-80 years) with clinically normal renal and hepatic function, the plasma AUC and peak plasma concentrations (C max) of irbesartan are approximately 20%-50% greater than those observed in younger subjects (18-40 years). Regardless of age, the elimination half-life is comparable. No significant age-related differences in clinical effect have been observed.In black and white normotensive subjects, the plasma AUC and t½ of irbesartan are approximately 20-25% greater in blacks than in whites; the peak plasma concentrations (C max) of irbesartan are essentially equivalent.In patients with renal impairment (regardless of degree) and in haemodialysis patients, the pharmacokinetics of irbesartan are not significantly altered. Irbesartan is not removed by hemodialysis.In patients with hepatic insufficiency due to mild to moderate cirrhosis, the pharmacokinetics of irbesartan are not significantly altered.CLINICAL TRIALSThe antihypertensive effects of irbesartan were examined in seven (7) major placebo-controlled 8-12 week trials in patients with baseline diastolic blood pressures of 95-110 mmHg.The seven (7) studies of irbesartan monotherapy included a total of 1915 patients randomised to irbesartan (1-900mg) and 611 patients randomised to placebo. Once daily doses of 150 to900mg provided statistically and clinically significant decreases in systolic and diastolic blood pressure with a plateau in effect at doses above 300mg.Systolic/diastolic mean decreases in blood pressure at trough (24 hours post-dosing), compared to placebo, following 6 to 12 weeks of treatment were in the range of 7.5-9.9/4.6-6.2 mmHg with a 150mg dose, and 7.9-12.6/5.2-7.9 mmHg with a 300mg dose.Once-daily dosing with 150mg gave trough and mean 24 hour responses corresponding to those observed in patients receiving twice-daily dosing at the same total daily dose. Peak (3-6 hour) effects were uniformly, but moderately, larger than trough effects, with the trough-to-peak ratio for systolic and diastolic response generally between 60-70%.Two of the seven placebo-controlled trials identified above and two additional studies examined the antihypertensive effects of irbesartan and hydrochlorothiazide in combination. Addition of a low dose of hydrochlorothiazide (12.5mg) to irbesartan (75 to 300mg) once daily resulted in further diastolic blood pressure reductions at trough (24 hours post-dosing) of 2.3-4.8 mmHg and an overall systolic/diastolic placebo-subtracted reduction of up to13.6/11.5 mmHg at a dose of 300mg irbesartan and 12.5mg hydrochlorothiazide. Once daily dosing with 150mg irbesartan and 12.5 mg hydrochlorothiazide gave systolic/diastolic mean placebo-adjusted blood pressure reductions at trough (24 hours post-dosing) of 12.9/6.9 mmHg.In patients not adequately controlled (SeDBP≥90 mmHg) on irbesartan (up to 300mg) alone, the addition of 12.5mg hydrochlorothiazide gave an added reduction of up to 6.1 mmHg in trough (24 hours) diastolic blood pressure.In patients not adequately controlled (SeDBP 93-120 mmHg) on 25mg hydrochlorothiazide alone, the addition of irbesartan (75-150mg) gave an added systolic/diastolic mean reduction of 11.1/7.2 mmHg.Analysis of age, gender and race subgroups of patients showed that men and women, and patients over and under 65 years of age, had generally similar responses.The effect of irbesartan is apparent after the first dose, substantially present within 1-2 weeks, and reaches a maximal effect within 4-6 weeks. In long-term studies the effect of irbesartan appeared to be maintained for more than one year. After withdrawal of irbesartan, blood pressure gradually returned towards baseline; no rebound was observed. There was essentially no change in average heart rate in irbesartan-treated patients in controlled trials. Hypertension and type II diabetic renal diseaseThe Irbesartan Diabetic Nephropathy Trial (IDNT) was a multicentre, randomised, controlled, double-blind, morbidity and mortality trial comparing AVAPRO, amlodipine and placebo. In 1715 hypertensive patients with type II diabetes (proteinuria ≥ 900mg/day and serum creatinine 110-265 µmol/L in men and 90-265 µmol/L in women) the long-term effects (mean 2.6 years) of AVAPRO on the progression of renal disease and all-cause mortality were examined. In addition, a secondary end-point, the effect of AVAPRO on the risk of fatal or non-fatal cardiovascular events was assessed. Patients were randomised to receive AVAPRO 75mg, amlodipine 2.5mg, or matching placebo once-daily. Patients were thentitrated to a maintenance dose of 300mg AVAPRO, 10mg amlodipine, or placebo as tolerated. Additional antihypertensive agents (excluding ACE inhibitors, angiotensin II receptor antagonists and calcium channel blockers) were added as needed to help achieve blood pressure goal (≤ 135/85 or 10 mmHg reduction in systolic blood pressure if higher than 160 mmHg) for patients in all groups. AVAPRO demonstrated a 20% relative risk reduction in the composite primary endpoint (first occurrence of any of the following: doubling of serum creatinine, end-stage renal disease or all-cause mortality) compared to placebo (95% CI (3%, 34%), p =0.023) and a 23% relative risk reduction compared to amlodipine (95% CI (7%, 37%), p = 0.006). When the individual components of the primary endpoint were analysed, no effect in all cause mortality was observed, while a positive trend in the reduction in ESRD and a significant reduction in doubling of serum creatinine were observed. Similar blood pressure was achieved in the AVAPRO and amlodipine groups. There was no significant difference in the assessment of fatal or non-fatal cardiovascular events (cardiovascular death, non-fatal myocardial infarction, hospitalization for heart failure, permanent neurologic deficit attributed to stroke, or above-the-ankle amputation) among the three treatment groups.The study of the Effects of Irbesartan on MicroAlbuminuria in Hypertensive Patients with Type 2 Diabetes Mellitus (IRMA 2) was a multicentre, randomised, placebo-controlled, double-blind morbidity study, conducted in 590 hypertensive patients with type II diabetes, microalbuminuria (20 - 200mcg/min; 30 - 300mg/day) and normal renal function (serum creatinine ≤ 130 µmol/L in males and ≤ 100 µmol/L in females). The study examined as a primary endpoint the long-term effects (2 years) of AVAPRO on the progression to (overt) proteinuria (urinary albumin excretion rate [AER] > 200µg/min [> approximately300mg/day] and an increase in AER of at least 30% from baseline). In addition, after one and two years of treatment, the effect of AVAPRO on the change in overnight AER and the change in 24-hour creatinine clearance was assessed. Patients were randomised to receive AVAPRO 150mg, AVAPRO 300mg, or matching placebo once daily. Additional antihypertensive agents (excluding ACE inhibitors, angiotensin II receptor antagonists and dihydropyridine calcium blockers) were added as needed to help achieve blood pressure goal (≤ 135/85 mmHg) for patients in all groups. AVAPRO 300mg demonstrated a 70% relative risk reduction in the development of clinical (overt) proteinuria compared to placebo (95% CI (39%, 86%), p = 0.0004). AVAPRO 150mg demonstrated a 39% relative risk reduction in the development of proteinuria compared to placebo (95% CI (-8%, 66%), p = 0.085). In the intent to treat analysis, when the primary endpoint is adjusted for urinary albumin excretion rate and mean arterial pressure, AVAPRO 300mg demonstrated a 68% relative risk reduction, (95% CI (35%, 85%), p=0.002). The slowing of progression to clinical (overt) proteinuria was evident as early as three months and continued over the 2 year period. The decline in 24-hour creatinine clearance did not differ significantly among the 3 groups. Regression to normoalbuminuria (< 20µg/min; <30mg/day) was more frequent in the AVAPRO 300mg group (34%) than in the placebo group (21%).The adverse experiences reported in these two studies are summarised under ADVERSE REACTIONS- Hypertension and Type II Diabetic Renal Disease and PRECAUTIONS - Effect on Laboratory Tests.INDICATIONSAVAPRO is indicated for the treatment of hypertension.AVAPRO is indicated for delaying the progression of renal disease in hypertensive type II diabetics with persistent micro-albuminuria (≥ 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.CONTRAINDICATIONSAVAPRO is contraindicated in patients who are hypersensitive to irbesartan or to any other component of the AVAPRO formulation.Pregnancy (See PRECAUTIONS-Use in Pregnancy)PRECAUTIONSHypotension - Volume-Depleted PatientsIrbesartan has been rarely associated with hypotension in hypertensive patients without other co-morbid conditions. Symptomatic hypotension, as with ACE inhibitors, may be expected to occur in sodium/volume-depleted patients such as those treated vigorously with diuretics and/or salt restriction, or on haemodialysis. Volume and/or sodium- depletion should be corrected before initiating therapy with irbesartan or a lower starting dose (e.g. 75 mg) should be considered. Patients undergoing haemodialysis should receive a starting dose of 75 mg and the dose should be adjusted according to B.P. response.Renal FunctionAs a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system (e.g., hypertensive patients with renal artery stenosis in one or both kidneys, or patients with severe congestive heart failure), treatment with drugs that affect this system has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. The possibility of a similar effect occurring with the use of an angiotensin II receptor antagonist, including irbesartan cannot be excluded.In hypertensive type II diabetic patients with proteinuria (≥ 900mg/day), a population which has a high risk of renal artery stenosis, no patient treated with AVAPRO in IDNT had an early acute rise in serum creatinine attributable to renal artery disease. (See CLINICAL TRIALS)Experience is limited with irbesartan in patients with moderate to severe renal impairment; careful monitoring of renal function and potassium in such patients is advised. HyperkalaemiaWhile hyperkalaemia in uncomplicated patients with hypertension has not been reported with irbesartan, hyperkalaemia may occur during treatment with other drugs that affect the renin-angiotensin-aldosterone system, especially in the presence of renal impairment and/or heart failure. Adequate monitoring of serum potassium in patients at risk is recommended.Cardiac DisordersThe safety of irbesartan in the presence of heart failure has not been fully defined. Sudden death has occurred in some studies of patients with heart failure, and although such deaths may have reflected the natural history of the underlying heart failure, caution is recommended when treating such patients with irbesartan.At this time, experience is limited with irbesartan in the treatment of patients with ventricular dysfunction or cardiac arrhythmias; caution is advised.Effects on FertilityFertility and reproductive performance were not affected in studies of male and female rats at oral doses of up to 650 mg/kg/day (approximately 3 (male) and 8 (female) fold higher exposure, based on AUC, than that of humans at the maximum recommended clinical dose of 300mg/day).Use in Pregnancy Category DDrugs that act directly on the renin-angiotensin system can cause foetal and neonatal morbidity and death when administered to pregnant women. Several dozen cases have been reported in the world literature in patients who were taking angiotensin-converting enzyme inhibitors. When pregnancy is detected, AVAPRO should be discontinued as soon as possible.The use of drugs that act directly on the renin-angiotensin system during the second and third trimesters of pregnancy have been associated with foetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios has also been reported, presumably resulting from decreased foetal renal function; oligohydramnios in this setting has been associated with foetal limb contractures, craniofacial deformation and hypoplastic lung development. Prematurity, intrauterine growth retardation and patent ductus arteriosus have also been reported, although it is not clear whether these occurrences were due to exposure to the drug.These adverse effects do not appear to have resulted from intrauterine drug exposure that has been limited to the first trimester. Mothers whose embryos and foetuses are exposed to an angiotensin II receptor antagonist only during the first trimester should be so informed. Nonetheless, when patients become pregnant, physicians should have the patient discontinue the use of AVAPRO as soon as possible.Infants with histories of in utero exposure to an angiotensin II receptor antagonist should be closely observed for hypotension, oliguria and hyperkalemia.When pregnant rats were treated with irbesartan from day 0 to day 20 of gestation, at doses of 50mg/kg/day and higher, transient effects (increased renal pelvic cavitation, hypoureter or subcutaneous oedema) were noted in full term rat foetuses but not in the young animals necropsied after 6 weeks of age. In pregnant rabbits, at doses of 30mg/kg/day, maternal mortality, abortion and early foetal resorptions were noted. No teratogenic effects were observed in the rat or rabbit.Use in LactationIrbesartan is excreted in the milk of lactating rats. It is not known whether irbesartan or its metabolites are excreted in human milk. A decision should be made whether to discontinue breast feeding or to discontinue the drug, taking into account the importance of irbesartan to the therapy of the mother and the potential risk to the infant.Paediatric UseSafety and effectiveness in paediatric patients have not been established.Use in the ElderlyAmong patients who received irbesartan in clinical studies, no overall differences in efficacy or safety were observed between older patients (65 years or older) and younger patients. GenotoxicityIrbesartan was not genotoxic in a series of assays for mutagenic and clastogenic effects. CarcinogenicityThe carcinogenic potential of irbesartan was assessed in two 104 week studies in mice and rats. No carcinogenic potential was observed in either species at doses of up to 500mg/kg/day (males rats) and 1000 mg/kg/day (mice and female rats) The AUC based exposure levels were 3 - 6 fold higher in mice, 3 fold higher in male rats and 25 fold higher in female rats than that of humans at the maximum recommended clinical dose of 300 mg/day.Effect on Laboratory TestsNo clinically significant changes in laboratory test parameters occurred in controlled clinical studies of hypertension. No special monitoring of laboratory parameters is necessary for patients with uncomplicated essential hypertension. Monitoring of potassium levels and renal function is recommended for patients with heart failure and those with moderate to severe renal impairment (see PRECAUTIONS).In two clinical studies of patients with hypertension and type II diabetic renal disease (IDNT and IRMA2) the following was reportedHyperkalaemia: In IDNT the percent of subjects with hyperkalaemia (>6 mmol/L) was 18.6% in the AVAPRO group compared to 6.0% in the placebo group. In IRMA 2 the percent of subjects with hyperkalaemia (>6 mmol/L) was 1.0% in the AVAPRO groups and none in the placebo group. In IDNT discontinuations due to hyperkalaemia in the AVAPRO group were 2.1% vs 0.36% in the placebo group. In IRMA 2 discontinuations due to hyperkalaemia in the AVAPRO groups were 0.5% vs none in the placebo group.INTERACTIONS WITH OTHER MEDICINESBased on in vitro data, no interactions would be expected to occur with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2D6, CYP2E1 or CYP3A4. Irbesartan is primarily metabolised by CYP2C9, however, during clinical interaction studies, no significant pharmacodynamic interactions were observed when irbesartan was co-administered with warfarin (a drug metabolised by CYP2C9).Irbesartan does not affect the pharmacokinetics of digoxin. The pharmacokinetics of irbesartan is not affected by coadministration with nifedipine or hydrochlorothiazide.Potassium-sparing diuretics, potassium supplements, potassium containing salt substitutes. Based on experience with the use of other drugs that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.LithiumReversible increases in lithium concentrations have been very rarely reported with irbesartan. Therefore if coadministration of AVAPRO and lithium proves necessary, careful monitoring of serum lithium levels is necessary.Combination use of ACE inhibitors or angiotensin receptor antagonists, anti-inflammatory drugs and thiazide diureticsConcomitant use of a renin-angiotensin system inhibiting drug (ACE-inhibitor or angiotensin receptor antagonist), and an anti-inflammatory drug (NSAID, including COX-2 inhibitor) alone or with a thiazide diuretic may increase the risk of renal impairment, including possible acute renal failure. These effects are usually reversible. This includes use in fixed-combination products containing more than one class of drug. The combination of these agents should be administered with caution, especially in the elderly, volume-depleted, and in patients with pre-existing renal impairment. Renal function (serum creatinine) should be monitored after initiation of concomitant therapy, and periodically thereafter. The antihypertensive effect of angiotensin II receptor antagonists, including irbesartan, may be attenuated by NSAIDs including selective COX-2 inhibitors.Effects on Ability to Drive or Use MachinesThe effect of irbesartan on ability to drive and use machines has not been studied. When driving vehicles or operating machines , it should be taken into account that occasionally dizziness or weariness may occur during treatment of hypertension.ADVERSE EFFECTSHypertensionIrbesartan has been evaluated for safety in approximately 5000 subjects in clinical studies, including 1300 hypertensive patients treated for over 6 months and over 400 patients treated for one year or more. Adverse events in patients receiving irbesartan were generally mild and transient with no relationship to dose. The incidence of adverse events was not related to age, gender, or race.In placebo-controlled clinical studies, including 1965 irbesartan-treated patients (usual duration of treatment 1 to 3 months), discontinuations due to any clinical or laboratory adverse event were 3.3 percent for irbesartan-treated patients and 4.5 percent for placebo-treated patients (p=0.029).Clinical adverse events, occurring in at least 1% of patients treated with irbesartan in placebo controlled trials are shown in the table below. The incidence of the same adverse events in the placebo control group is also shown.Clinical Adverse Events* in Placebo-Controlled Hypertension TrialsIncidencePercentage (%) of Patients*BODY SYSTEM/EVENT Irbesartann=1965Placebon=641GeneralFatigueInfluenza Chest pain 4.32.31.83.72.01.7CardiovascularOedemaTachycardia 1.51.22.30.9GastrointestinalDiarrhoeaNausea/VomitingDyspepsia/Heartburn Abdominal Pain 3.12.11.71.42.22.81.12.0Nervous SystemDizzinessHeadache aAnxiety/Nervousness 4.912.31.15.016.70.9DermatologicalRash 1.3 2.0 Musculoskeletal/ConnectiveMusc/Skel PainMusc/Skel Trauma a 6.61.96.60.5Renal/GenitourinaryUTI 1.1 1.4 RespiratoryUpper Resp. Infection Sinus AbnormalityCoughPharyngitisRhinitis 8.53.42.82.21.96.25.02.72.52.8a Statistically significant difference between irbesartan and placebo treatment groups.Adverse reactions that occurred in 2 or more hypertensive patients in clinical trials involving 3396 patients have been classified using standard terminology and in the following listing are categorised by body system and listed in order of decreasing frequency according to the following definitions: common adverse reactions are those occurring on one or more occasions in at least 1/100 but less than 1/10 patients; uncommon adverse reactions are those occurring in at least 1/1000 but less than 1/100 patients; rare adverse reactions are those occurring in less than 1/1000 patients.Cardiovascular : Uncommon: subjective rhythm disturbance, flushing, ECG abnormality, cardiac murmur, cardiac rhythm disturbance, orthostatic hypotension, atrial rhythm disturbance, bradycardia, hypotension; Rare:syncope, conduction disorder, myocardial infarction.Dermatologic : Uncommon: pruritus, facial erythema; Rare: dermatitis, acne,scalp-hair abnormality.Endocrine/Metabolic/Electrolyte Imbalance : Uncommon: sexual dysfunction, libido change; Rare: breast disorder, gout, hot flashes.Gastrointestinal :Uncommon: constipation, flatulence, dry mouth, abdomen distention; Rare: abnormal stool, decreased appetite, increased appetite, oral lesion, dysphagia, oesophagitis.General : Uncommon: weakness, hyperhidrosis, malaise, weight gain; Rare: cold sensation, warmth sensation, pain.Hematopoietic : Rare: anaemia.Immunology/Sensitivity Disorder : Uncommon: upper extremity oedema ; Rare: head/neck oedema.Musculoskeletal/Connective Tissue : Uncommon: muscle cramp, swelling extremity; Rare: arthritis, muscle ache, myalgia, extremity weakness, stiffness lower extremity.Nervous System : Uncommon: orthostatic dizziness, numbness, sleep disturbance, depression, emotion labile/disturbance, somnolence, vertigo, paresthesia; Rare: stress related disorder, tremor, coordination disturbance, disturbing dreams.Renal/Genitourinary : Uncommon: urination abnormality.Respiratory : Uncommon: epistaxis, dyspnea.Special Senses : Uncommon: vision disturbance, hearing abnormality; Rare: eye disturbance -other, eyelid abnormality, visual field abnormality, medication bad taste, taste disturbance. Hypertension and Type II Diabetic Renal DiseaseIn clinical studies (see CLINICAL TRIALS, Hypertension and type II diabetic renal disease), the adverse experiences were similar to those in clinical trials of hypertensive patients with the exception of orthostatic symptoms (dizziness, orthostatic dizziness and orthostatic hypotension) observed in IDNT (proteinuria ≥ 900mg/day, and serum creatinine from 90 - 265 µmol/L). In IDNT orthostatic symptoms occurred more frequently in the AVAPRO。

TA Instruments产品说明书

New Castle, DE USA Lindon, UT USA Crawley, United Kingdom Shanghai, China Beijing, ChinaTaipei, TaiwanTokyo, JapanSeoul, Korea Bangalore, IndiaParis, France Eschborn, Germany Brussels, BelgiumEtten-Leur, Netherlands Sollentuna, Sweden Milano, Italy Barcelona, Spain Melbourne, Australia Mexico City, MexicoDifferential Scanning Calorimetry (DSC) Q20004 Q206 DSC Technology8 Accessories10 Temperature Control Options14 Tzero®& MDSC® Technology18 Applications20Thermogravimetric Analysis (TGA) Q5000 IR32 Q50034 Q5036 Q5000 IR Technology38 Performance42 Q500 / Q50 Technology44 TGA Accessories & Options46 Applications52 TGA-HP58 Applications60Simultaneous DSC/TGAQ60064 SDT Technology66 Applications68Vapor Sorption AnalysisVTI-SA+72 VTI-SA+Technology74 Q5000 SA78 Q5000 SA Technology80 Applications86 Dynamic Mechanical Analysis (DMA) Q80092 Deformation Modes & Sample Size94 Subambient Operation95 Q800 Technology96 Modes of Deformation98 Accessories100 DMA Theory104 Modes of Operation105 Applications106Thermomechanical Analysis (TMA) Q400EM / Q400112 Q400 Technology114 Modes of Deformation116 TMA Theory / Modes of Operation118 Applications122CALORIMETRYDSC Q2000 SPECIFICATIONS TechnologiesTzero ®TechnologyAdvanced MDSC ®Available Direct Cp MeasurementIncluded Platinum™ Software IncludedHardware Features SVGA Touch Screen Included User Replaceable Tzero Cell Yes 50-Position Autosampler Available Autolid Included Dual Digital Mass Flow Controllers Included Full Range of Cooling Accessories (LNCS, RCS90, RCS40, FACS, QCA)Available Pressure DSC Available Photocalorimeter Available Performance Temperature Range Ambient to 725 ˚C With Cooling Accessories -180 to 725 ˚C Temperature Accuracy +/- 0.1 ˚C Temperature Precision +/- 0.01 ˚C Calorimetric Reproducibility (indium metal)+/- 0.05 %Calorimetric Precision (indium metal)+/- 0.05 %Dynamic Measurement Range>+/- 500 mW Baseline Curvature (Tzero; -50 to 300 ˚C)10 μW Baseline Reproducibility with Tzero+/- 10 μW Sensitivity 0.2 μW Indium Height / Width (mW/˚C)* 60The Q2000 is a research-grade DSC with superiorperformance in baseline flatness, precision,sensitivity, and resolution. Advanced Tzero ®technology and multiple exclusive hardware andsoftware features make the Q2000 powerful,flexible, and easy-to-use. Modulated DSC ®anda reliable 50-position autosampler are availableas options. An additional high-value feature isPlatinum™ software, which permits automaticscheduling of tests designed to keep the Q2000consistently in top operating condition. Availableaccessories, such as a new photocalorimeter,pressure DSC, and the widest array of coolingdevices, make the Q2000 a DSC well-equippedto satisfy the most demanding researcher.*Indium height/width ratio: 1.0 mg In heated at 10 ˚C/min in N 2atmosphere. (A larger number denotes better performance).DSC Q20 SPECIFICATIONSHardware FeaturesQ20AQ20Q20P Tzero ®Cell (ﬁxed position)Included Included—User Replaceable Cell——Yes 50-Position Autosampler —Included—Autolid —Included—Dual Digital Mass Flow Controllers Included Included—Full Range of Cooling Accessories Available AvailableQCA Only (LNCS, RCS90, RCS40, FACS, QCA)Pressure DSC ——Yes Platinum Software —Included—MDSC Available Available —Performance Temperature Range Amb to 725 ˚C Amb to 725 ˚C Amb to 725 ˚C With Cooling Accessories -180 to 725 ˚C -180 to 725 ˚C -130 to 725 ˚C Temperature Accuracy +/- 0.1 ˚C +/- 0.1 ˚C +/- 0.1 ˚C Temperature Precision +/- 0.05 ˚C +/- 0.05 ˚C +/- 0.05 ˚C Calorimetric Reproducibility (indium metal)+/- 1 % +/- 1 %+/- 1 %Calorimetric Precision (indium metal)+/- 0.1 %+/- 0.1 %+/- 0.1 %Dynamic Measurement Range +/- 350 mW +/- 350 mW +/- 350 mW Digital Resolution>0.04μW >0.04μW >0.04μW Baseline Curvature (-50 to 300 ˚C)<0.15 mW <0.15 mW —Baseline Reproducibility< 0.04 mW <0.04 mW —Sensitivity1.0 μW 1.0 μW 1.0 μW Indium Height / Width (mW/˚C)* 8.08.0—*Indium height/width ratio: 1.0 mg In heated at 10 ˚C/min in N 2atmosphere. (A larger number denotes better performance).The Q20 (Q20, AQ20, Q20P) is a cost-effective,easy-to-use, general-purpose DSC module, with calorimetric performance superior to many competitive research-grade models. These are entry-level instruments not based on performance,but on available options. The Q20 is idealfor research, teaching, and quality controlapplications that require a rugged, reliable, basicDSC. The AQ20 is designed for unattendedanalysis of up to 50 samples in a sequentialmanner. The Q20 and AQ20 include dual digitalmass flow controllers and are available withMDSC ®. The Q20P is designed for studies ofpressure-sensitive materials or samples that mayvolatilize on heating.Cooling Rods Cooling Ring Furnace Tzero Thermocouple Constantan Sensor Chromel Area ThermocouplePhotocalorimeterThe Photocalorimeter Accessory (PCA), for the Q2000 DSC, permits characterizationof photocuring materials between -50 and 250 ˚C. UV/Visible light (250-650 nm) froma 200W high pressure mercury source is transmitted to the sample chamber via anextended range, dual-quartz light guide with neutral density or band pass filters. Tzero ®technology permits direct measurement of light intensity at both the sample and referencepositions. It also provides for simultaneous measurement of two samples.RCS40 ArrayRCS90TZERO ®DSC PERFORMANCE APPLICATIONSMDSC ®APPLICATIONSSTANDARD PANS/LIDS APPLICATIONSDSC pans & lids are available in aluminum, alodine-coated aluminum, gold, platinum, graphite, and stainless steel versions. They can be used under a variety of temperature and pressure conditions. Samples can be run in the standard DSC mode in open pans, crimped or hermetically sealed pans / lids or in pressure capsules. Samples in open pans can also be run at controlled pressures using the PDSC Cell. All aluminum standard pans have the same temperature and pressure rating. General details of the pans are shown here.TZERO ®PANS/LIDS APPLICATIONS© 2010 TA Instruments. All rights reserved.L90010.001。

吉玛重组腺病毒操作手册说明书

如有疑问欢迎垂询上海电话：************-8009苏州电话：*************-8042E-mail：************************** E-mail：************************吉玛重组腺病毒操作手册GenePharma Recombinant Adenovirus Operation Manual2017 年 6 月如有疑问欢迎垂询上海电话：************-8009苏州电话：*************-8042E-mail：**************************E-mail：************************目录一、产品简介 (4)二、腺病毒载体优势 (4)三、生物安全性 (5)3.1安全性 (5)3.2实验室安全措施 (5)四、流程描述 (6)五、材料与仪器 (7)5.1实验材料 (7)5.1.1细胞株 (7)5.1.2质粒 (7)5.1.3试剂 (8)5.2实验耗材及仪器 (8)5.2.1耗材 (8)5.2.2仪器 (9)六、具体步骤 (9)6.1细胞培养 (9)6.1.1活细胞计数 (9)6.1.2细胞株的冻存 (9)6.1.3细胞复苏 (10)6.1.4细胞传代 (10)6.2病毒包装 (10)6.3病毒收集 (11)6.4病毒扩增 (12)6.5病毒纯化 (12)6.6病毒重悬和保存 (13)6.7病毒滴度检测 (13)七、使用方法 (14)如有疑问欢迎垂询上海电话：************-8009苏州电话：*************-8042E-mail：************************** E-mail：************************重组腺病毒在细胞水平使用 (14)7.1病毒滴度复核（有限稀释法测定） (14)7.2靶细胞感染预实验 (16)7.3正式试验 (18)八、运输和储存 (18)九、常见问题及解决方案 (19)十、吉玛案例 (20)十一、附录 (21)如有疑问欢迎垂询上海电话：************-8009苏州电话：*************-8042E-mail：************************** E-mail：************************一、产品简介腺病毒(Adenovirus，Adv)是一种线性双链DNA 病毒。

High-powerlithiumbatteriesfromfunctionalizedcarbon-nanotubeelectrodes

High-power lithium batteries from functionalized carbon-nanotube electrodesSeung Woo Lee 1†,Naoaki Yabuuchi 2†,Betar M.Gallant 2,Shuo Chen 2,Byeong-Su Kim 1,Paula T.Hammond 1and Yang Shao-Horn 2,3*Energy storage devices that can deliver high powers have many applications,including hybrid vehicles and renewable energy.Much research has focused on increasing the power output of lithium batteries by reducing lithium-ion diffusion distances,but outputs remain far below those of electrochemical capacitors and below the levels required for many applications.Here,we report an alternative approach based on the redox reactions of functional groups on the surfaces of carbon yer-by-layer techniques are used to assemble an electrode that consists of additive-free,densely packed and functionalized multiwalled carbon nanotubes.The electrode,which is several micrometres thick,can store lithium up to a reversible gravimetric capacity of ∼200mA h g 21electrode while also delivering 100kW kg electrode 21of power and providing lifetimes in excess of thousands of cycles,both of which are comparable to electrochemical capacitor electrodes.A device using the nanotube electrode as the positive electrode and lithium titanium oxide as a negative electrode had a gravimetric energy ∼5times higher than conventional electrochemical capacitors and power delivery ∼10times higher than conventional lithium-ion batteries.Amajor challenge in the ﬁeld of electrical energy storage is to bridge the performance gap between batteries and electroche-mical capacitors by developing materials that can combine the advantages of both devices.Batteries exhibit high energy as a result of Faradaic reactions in the bulk of active particles,but are rate-limited.Electrochemical capacitors 1–3can deliver high power at the cost of low energy storage by making use of surface ion adsorption (referred to as double-layer capacitance)and surface redox reactions (referred to as pseudo-capacitance).Lithium rechargeable batteries ( 150W h kg cell 21and 1kW kg cell 21)therefore have higher gravimetric energy but lower power capability than electrochemical capacitors ( 5W h kg cell 21and 10kW kg cell 21)1.Energy and power versatility are crucial for hybrid applications 2.For example,although conventional batteries have been used in light vehicles,hybrid platforms for heavy vehicles and machineries demand delivery of much higher currents,so higher energy and comparable power capability relative to electrochemical capacitors are needed to meet this demand 1,2.Considerable research efforts have been focused on increasing the power characteristics of lithium rechargeable batteries by redu-cing the dimensions of lithium storage materials down to the nano-metre scale 4–12,which would reduce the lithium diffusion time that accompanies the Faradaic reactions of active particles.However,nanostructured lithium storage electrodes 5,13still have a lower power capability than electrochemical capacitor electrodes.On the other hand,researchers have shown that the gravimetric energy of electrochemical capacitors can be increased by using electrode materials with enhanced gravimetric capacitances (gravimetric charge storage per volt),which can be achieved through the use of carbon subnanometre pores for ion adsorption 1,14or by taking advantage of the pseudocapacitance of nanostructured transition metal oxides 15–17.The high cost of ruthenium-based oxides is prohibitive for many applications,and the cycling instability of manganese-based oxides 17–19remains a major technical challenge.A promising approach is to use the Faradaic reactions of surface functional groups on nanostructured carbon electrodes,which can store more energy than the double-layer capacitance on convention-al capacitor electrodes 1and also provide high power capability.Here,we report the use of an entirely different class of electrodes for lithium storage,which are based on functionalized multiwalled carbon nanotubes (MWNTs)that include stable pseudo-capacitive functional groups,and are assembled using the layer-by-layer (LBL)technique 20.These additive-free LBL-MWNT electrodes exhibit high gravimetric energy (200W h kg electrode 21)delivered at an exceptionally high power of 100kW kg electrode 21in Li /LBL-MWNT cells when normalized to the single-electrode weight,with no loss observed after completing thousands of cycles.LBL-MWNT electrodes show signiﬁcantly higher gravimetric energy not only over electrochemical capacitor electrodes,but also over high-power lithium battery electrodes,with gravimetric powers greater than 10kW kg electrode 21.In addition,cells (analogous to asymmetric electrochemical capacitors)consisting of LBL-MWNTs and a lithiated Li 4Ti 5O 12(LTO)negative electrode have comparable gravimetric energy to LTO /LiNi 0.5Mn 1.5O 4cells 21at low gravimetric power,but can also deliver much higher energy at higher power.Gravimetric energy and power at the cell level may be estimated by dividing these values based on LBL-MWNT weight by a factor of 5(ref.22).Furthermore,we show that the Faradaic reactions between the lithium ions and the surface functional groups on the MWNTs are responsible for the high gravimetric energy found in Li /LBL-MWNT and LTO /LBL-MWNT cells.Physical characteristics of LBL-MWNT electrodesStable dispersions of negatively and positively charged MWNTs were obtained by functionalization of the exterior surfaces with car-boxylic-acid (MWNT–COOH)and amine-containing (MWNT–NH 2)groups,respectively 23.Uniform MWNT electrodes on glass1Department of Chemical Engineering,Massachusetts Institute of T echnology,Cambridge,Massachusetts 02139,USA,2Department of Mechanical Engineering,Massachusetts Institute of T echnology,Cambridge,Massachusetts 02139,USA,3Department of Materials Science and Engineering,Massachusetts Institute of T echnology,Cambridge,Massachusetts 02139,USA;†These authors contributed equally to this work.*e-mail:shaohorn@coated with indium tin oxide (ITO)(Fig.1a)were assembled by alternate adsorption of charged MWNTs 23.Electrode thickness increases linearly with the number of positively and negatively charged layer pairs (bilayers),as shown in Fig.1b.The transparency of the MWNT ﬁlms decreased linearly with increasing thickness up to 0.3m m (Fig.1b).The ﬁlms were then heat-treated sequentially at 1508C in vacuum for 12h,and at 3008C in H 2for 2h to increase ﬁlm mechanical stability and electrical conductivity bined proﬁlometry and quartz crystal microbalance measurements gave an electrode density of 0.83g cm 23(Supplementary Fig.S1)follow-ing the heat treatments,which is one of the highest densities reported for carbon nanotube electrodes 24,25.Cross-sectional scan-ning electron microscope (SEM)images showed that the individual MWNTs were randomly distributed throughout the ﬁlm thickness,and the MWNT ﬁlms were uniform and conformal on the substrate (Fig.1c).Moreover,the LBL-MWNT electrodes had an inter-connected network of individual MWNTs (Fig.1c,inset)with well-distributed pores of 20nm,as revealed by transmission electron microscopy (TEM)imaging of an LBL-MWNT electrode slice (Fig.1d).Role of surface functional groups on LBL-MWNTelectrodesX-ray photoemission spectroscopy (XPS)analysis of the LBL-MWNT electrodes after heat treatment revealed that signiﬁcant amounts of oxygen-containing and nitrogen-containing surface functional groups remained on the nanotube surface.The atomic composition of a representative LBL-MWNT electrode was found to be 85.7%carbon,10.6%oxygen and 3.7%nitrogen (C 0.86O 0.11N 0.04;Supplementary Table S1).The presence of two dis-tinct peaks (531.7+0.1eV and 533.4+0.1eV)in the O 1s spectrum (Supplementary Fig.S2a)could be attributed to oxygen atoms inthe carbonyl groups 26,27and various other oxygen groups (Supplementary Fig.S2c)bound to the edges 26,28of the graphene sheets forming the MWNT sidewalls.High-resolution TEM images of functionalized MWNTs revealed that acid treatments roughened the exterior walls of the MWNTs (Supplementary Fig.S3),exposing carbon atoms on the edge sites.Edge carbon atoms are known to bind with oxygenated species more strongly than carbon atoms in the basal plane 29,which is in good agreement with the XPS ﬁnding that more oxygenated species are detected on LBL-MWNT electro-des than on pristine MWNTs.In addition,the chemical environment of the nitrogen atoms in the LBL-MWNT electrodes was mostly in the form of amide groups (Supplementary Fig.S2b),as indicated by the N 1s peak centred at 400.1eV (ref.30).Two small additional peaks in the N 1s spectrum suggest that some nitrogen atoms are pyr-idinic N-6(ref.30)(398.5+0.1eV)and tied in oxidized nitrogen-containing functional groups (402.3eV)30.These surface functional groups can undergo Faradaic reactions,as indicated by the potential-dependent gravimetric capacitance obtained from cyclic voltammetry measurements (Fig.2a).The typical gravi-metric capacitance of LBL-MWNT electrodes in the voltage range 3–4.25V versus Li (with a comparable voltage scale of 0to 1.2V versus standard hydrogen electrode (SHE))is 125F g 21,which is comparable to the values reported for functionalized MWNTs 23,31and porous carbon materials 32,33in aqueous solutions.Reducing the lower potential limit from 3.0to 1.5V led to a signiﬁcant increase in the gravimetric capacitance from 125to 250F g 21measured at 4.0and 2.5V versus Li.Recent studies have shown that carbonyl (C ¼O)groups can be reduced by Li þand reversibly oxidized in the voltage range from 3.5to 1.5V versus Li in aromatic carbonyl derivative organic materials such as poly(2,5-dihydroxy-1,4-benzoqui-none-3,6-methylene)34and Li 2C 6O 6(ref.35).It is thereforepostulated0.00.51.01.52.02.53.03.5acbdT h i c k n e s s (µm )Number of bilayersFigure 1|Physical characteristics of LBL-MWNT electrodes.a ,Digital image of representative MWNT electrodes on ITO-coated glass slides.The number on each image indicates the number of bilayers (n )in (MWNT–NH 2/MWNT–COOH)n .b ,Thickness of the LBL-MWNT electrodes as a function of the number of bilayers.A linear relationship is apparent for LBL-MWNT electrodes with thicknesses from 20nm to 3m m.Error bars show the standard deviation of the thickness,computed from three samples for each thickness.T ransmittance measured at 550nm as a function of the number of bilayers is shown in the inset.Error bars show the standard deviation of transmittance computed from three measurements.c ,SEM cross-sectional image of an LBL-MWNT electrode on an ITO-coated glass slide after heat treatments.A higher-magniﬁcation image is shown in the inset,revealing that MWNT s are entangled in the direction perpendicular to the electrode surface.d ,TEM image of an LBL-MWNT electrode slice,showing pore sizes of the order of 20nm.DOI:10.1038/NNANO.2010.116that the doubled gravimetric capacitance obtained from lowering the lower voltage limit of Li /LBL-MWNT cells (with open-circuit voltages of 3.2V)from 3.0to 1.5V versus Li can be attributed to the Faradaic reactions of surface oxygen on LBL-MWNTs,such as C ¼O LBL-MWNT þLi þþe 2↔C 2OLi LBL-MWNT ,which can become accessible at vol-tages lower than 3V versus Li.The role of surface functional groups in providing high capaci-tances in LBL-MWNTs was further conﬁrmed by comparing the speciﬁc capacitance of LBL-MWNTs before and after exposure to 4%H 2and 96%Ar by volume at 5008C for 10h.The gravimetric current and capacitance values of the LBL-MWNTelectrode decreased considerably (by 40%)after this heat treatment,as shown in Fig.2b.XPS analysis showed that this high-temperature heat treatment decreased the amount of surface oxygen and nitrogen functional groups on the MWNTs.The intensities of the distinct C 1s peaks (assigned to carbon atoms in C 2N (ref.36)or C 2O (ref.37)centred at 285.9+0.1eV,carbonyl C ¼O (refs 27,37)groups at 286.7+0.1eV,and amide N 2C ¼O or carboxylic COOR groups at 288.4+0.1eV (ref.36))were greatly reduced (by 70%)relative to those of sp 2(284.5eV)and sp 3(285.2eV)hybridized carbon 37follow-ing heat treatment,as shown in Fig.2c.This experiment therefore pro-vides further evidence that the redox of surface oxygen-containing functional groups with lithium ions is responsible for the large gravi-metric capacitances of LBL-MWNT electrodes in organic electrolytes.The contribution of double-layer capacitance to LBL-MWNT capacitances is relatively small compared to that of Faradaic reactions,and can be estimated by comparing cyclic voltammograms of compo-site electrodes (80wt%MWNTs and 20wt%binder)that include pristine MWNTs with those containing functionalized MWNTs(see Supplementary Information).Composite electrodes with MWNT–COOH and MWNT–NH 2show much higher gravimetric capacitances (factor of 2)than pristine MWNTs (Fig.2d;Supplementary Fig.S4),indicating the dominant contribution from the surface functional groups.In addition,we show that surface func-tional groups on MWNTs are better used in LBL-MWNT electrodes than in composite electrodes.The capacitance normalized to MWNT weight for LBL-MWNT electrodes is 2.5times higher than that of con-ventional composite electrodes (Fig.2d).Considering that the MWNT–COOH and MWNT–NH 2in the composite electrodes have similar ratios of carbon and oxygen atomic percentages as the LBL electrodes (Supplementary Table S1),this result suggests that the binder-free porous network structure of LBL-MWNT electrodes allows better utilization of the surface functional groups than compo-site electrodes with binder,which can block the redox of the surface functional groups.Moreover,the volumetric capacitances of LBL-MWNT electrodes are even greater (by a factor of 5)than those of composite MWNT electrodes because of their higher elec-trode density (0.83g cm 23for LBL-MWNTs versus 0.45g cm 23for composite electrodes).Lithium storage characteristics of LBL-MWNT electrodesThe speciﬁc and volumetric capacitances of LBL-MWNT electrodes are greater than those of conventional composite electrodes based on carbon 32,38in organic electrolytes.Because LBL-MWNT electrodes have no additives,the gravimetric capacitance normalized to electrode weight is identical to that normalized to MWNT weight.It is interesting to point out that the gravimetric capacitances of these LBL-MWNT electrodes are comparable to those of12345−1.0−0.50.00.51.0acbdI (A g M W N T −1)I (A g M W N T −1)I (A g M W N T −1)E (V versus Li)−1,000−50005001,0001.48 ± 0.14 µm at 1 mV s −10.31 ± 0.01 µm at 1 mV s −10.31 ± 0.01 µm at 1 mV s −1PVdF-MWNT (pristine)PVdF-MWNT (−NH 2)PVdF-MWNT (−COOH)3.0 −4.25 VBefore 500 °C H 2 treatmentBefore 500 °C H 2 treatment After 500 °C H 2 treatmentAfter 500 °C H 2 treatment4.2 V4.5 V4.5 V4.2 V d Q /d E (F g MWNT −1)d Q /d E (F g MWNT −1)d Q /d E (F g MWNT −1)12345−0.6−0.30.00.30.6−600−300300600E (V versus Li)292290288286284282C 1s LBL-MWNTC−NN−C C−O sp 2−Csp 3−CI n t e n s i t y (a .u .)Binding energy (eV)12345−1.0−0.50.00.51.0−1,000−5005001,000E (V versus Li)−−O−−O COOR C Figure 2|Potential-dependent electrochemical behaviour of LBL-MWNT and functionalized MWNT composite electrodes measured in two-electrode lithium cells.a ,Cyclic voltammogram data for an LBL-MWNT electrode obtained with different upper-and lower-potential limits.Reducing the lower-potential limit from 3to 1.5V versus Li resulted in increased current and gravimetric capacitance.b ,Cyclic voltammogram data for an LBL-MWNT electrode before and after 5008C H 2-treatment in 4%H 2and 96%Ar by volume for 10h.c ,XPS C 1s spectra of an LBL-MWNT electrode before and after this additional heat treatment,which is seen to remove a considerable amount of surface oxygen and nitrogen functional groups from the MWNT surface.d ,Cyclic voltammogram data for an LBL-MWNT electrode and composite electrodes of pristine MWNT,MWNT–COOH and MWNT–NH 2,with the LBL-MWNT electrode having higher current and capacitance normalized to the MWNT weight than the composite electrodes.The composite electrodesconsisted of 20wt%PVdF and 80wt%posite MWNT electrodes were prepared from slurry casting and dried at 1008C for 12h under vacuum.The thickness of the LBL-MWNT electrode was 0.3m m,and the thicknesses of the pristine MWNT,MWNT–COOH and MWNT–NH 2composite electrodes were 40,50and 30m m,respectively.The density of the composite electrodes was 0.45g cm 23.DOI:10.1038/NNANO.2010.116nanostructured composite electrodes with manganese-based oxides ( 40wt%oxides),even though higher capacitances normalized toactive material mass only (for example,up to 600F g MnO221;ref.39)are typically reported.Moreover,taking into account the LBL-MWNT electrode density of 0.83g cm 23,we obtain a volumetric capacitance of 180F cm 23for LBL-MWNT electrodes,which is higher than that of nanostructured carbon ( 50F cm 23)in organic electrolytes 32and nanostructured MnO 2electrodes( 150F cm 23)in aqueous electrolytes 16,40.Very few studies have reported the volumetric capacitance of entire electrodes,and we note that this is,to our knowledge,the highest value reported.Storing energy on the surfaces of MWNTs enables LBL-MWNT electrodes to have a high rate capability.For a given thickness,the current at 3V was found to increase linearly with scan rate from cyclic voltammetry,indicating a surface-redox limited process (Fig.3a,including inset),which is in good agreement with the proposed mechanism of redox of functional groups on MWNT surfaces.LBL-MWNT electrodes were also examined by means of galvanostatic measurements,allowing direct comparison with the performance of high-power battery materials.The gravi-metric capacity of 0.3-m m electrodes was found to be 200mA h g 21at low rates such as 0.4A g 21,which is in good agreement with the estimated capacity of LBL-MWNT electrodes based on the proposed Faradaic reaction between Li and surface oxygen (C 0.86O 0.11N 0.04).Half of the gravimetric capacity (100mA h g 21)was retained at exceptionally high discharge rates of 180A g 21(corresponding to full discharge in less than 2s),as shown in Fig.3b.Moreover,the capacity (stored charge)of LBL-MWNT electrodes increases linearly with electrode thickness (Fig.3c,inset),and a high power capability is maintained with elec-trode thickness increasing to 3m m (Supplementary Fig.S5).The speciﬁc energy and power of LBL-MWNTelectrodes with thick-nesses up to 3.0m m,in the 1.5–4.5V range,are shown in Fig.4a (for volumetric energy and power data see Supplementary Fig.S7).Although the powercapabilityof LBL-MWNTelectrodes reduces some-what with increasing thickness,electrodes of 3.0m m can still deliver a very high gravimetric energy of 200W h kg electrode 21at a large gravimetric power of 100kW kg electrode 21,based on single-electrode weight alone.At low powers,their gravimetric energy ( 500W h kg electrode 21)approaches that of LiFePO 4and LiCoO 2(refs 5,35,41;Supplementary Fig.S6).At high powers (greater than 10kW kg electrode 21),LBL-MWNT electrodes show higher gravimetric energy than carbon-nanotube-based electrodes for electrochemical capacitors ( 70W h kg electrode 21;ref.25),thin-ﬁlm batteries 22,nano-structured lithium battery materials 5,13and high-power lithium battery materials 4,42(Supplementary Fig.S6).As conventional composite electrodes are much thicker than the 3.0-m m LBL-MWNT elec-trodes (.10times),where ion transport in the electrodes can limit power capability,future studies are needed to examine how the power and energy performance of LBL-MWNT electrodes changes with thicknesses up to tens and hundreds of micrometres.LBL-MWNT electrodes can be tested over 1,000cycles without any observable capacity loss,as shown in Fig.4b.Further cycling of a 1.5-m m LBL-MWNT electrode revealed no capacity loss up to 2,500cycles,even after the cell was left open circuit for 30days (Supplementary Fig.S8).The voltage proﬁles in the ﬁrst and 1,000th cycles to 4.5V are virtually unchanged (Fig.4c and Supplementary Fig.S8).TEM and XPS analysis of cycled electro-des (1,000cycles to 4.5V,followed by an additional 1,000cycles to 4.7V versus Li)provided further evidence for this cycling stab-ility,with no distinctive change being noted in the surface atomic structure and surface functional groups after cycling (Supplementary Fig.S9).The stability of the functional groups on these MWNTs is remarkable when compared to the consider-able losses of carbonyl derivative molecules within 50to 100cycles reported recently 34,35,43.We hypothesize that the cycling stability of the LBL-MWNT electrodes can be linked to the strong chemical covalent bonding of the surface functional groups on the MWNTs,in contrast to the gradual separation occurring between the active carbonyl groups and carbon addi-tives in composite electrodes during cycling.Because a lithium negative electrode is not practical for real applications,we investigated the use of LBL-MWNT electrodes with a lithiated Li 4Ti 5O 12(LTO)composite electrode (see−1.0−0.50.00.51.0a bE (V versus Li)I (m A )249 A g −1183 A g −137 A g −14.5 V(0.31±0.01 µm)550 A g −12 A g −10.4 A g −16012345E (V v e r s u s L i )E (V versus Li)70140210Q (mA h g −1)Q (µA h)12345−80−404080I (µA )c Figure 3|Electrochemical characteristics of LBL-MWNT electrodes in two-electrode lithium cells with 1M LiPF 6in a mixture of ethylene carbonate and dimethyl carbonate (volume ratio 3:7).a ,Cyclicvoltammogram data for a 0.3-m m LBL-MWNT electrode over a range of scan rates.The current at 3V versus scan rate is shown in the inset.b ,Charge and discharge proﬁles of an electrode of 0.3m m obtained over a wide range of gravimetric current densities between 1.5and 4.5V versus Li.Before each charge and discharge measurement for the data in Fig.3b,cells were held at 1.5and 4.5V for 30min,respectively.c ,Cyclic voltammogram data forelectrodes with different thicknesses collected at a scanning rate of 1mV s 21in the voltage range 1.5–4.5V versus Li.The integrated charge increases linearly with electrode thickness,as shown in the inset.DOI:10.1038/NNANO.2010.116Supplementary Information).Although the electrode gravimetric energy and power in LTO /LBL-MWNT cells is reduced due to the lower cell voltage (Fig.4d),the rate capability,gravimetric capacity and capacity retention are comparable to cells with a Li negative electrode (Supplementary Fig.S10).Interestingly,although LTO /LBL-MWNT cells show comparable gravimetric energy to LTO /LiNi 0.5Mn 1.5O 4cells at low power,they exhibit signiﬁcantly higher gravimetric energy at powers greater than10kW kg electrode 21(ref.21;Fig.4d and Supplementary Fig.S11).Using a conservative assumption that the mass of the battery is ﬁve times greater than that of the LBL-MWNT 22,which is higher than the 2.5(ref.4)typically used for conventional lithium rechargeable batteries due to reduced electrode thicknesses (such as 3m m)demonstrated in this study,LTO /LBL-MWNT storage devices are expected to deliver 30W h kg cell 21at 5kW kg cell 21.This value is signiﬁcantly higher than that of current electrochemical capacitors with a gravimetric energy of 5W h kg cell 21at 1kW kg cell 21(refs 1,32).Finally,we show that LBL-MWNT electrodes can also be used in symmetrical LBL-MWNT /LBL-MWNT cells (cell voltage in the range 0–3V).As there is no net Faradaic reaction of surface oxygen-containing functional groups on MWNTs,they exhibit speciﬁc capacitances ( 95F g 21)comparable to those (702120F g 21)in electrochemical capacitors reported previously 44,but considerably lower than that of Li /LBL-MWNT cells.Symmetric cells therefore deliver gravimetric energy comparable toconventional electrochemical capacitors 1,32,but lower than Li /LBL-MWNT and LTO /LBL-MWNT cells (Fig.4d).ConclusionsIn summary,LBL-MWNT electrodes,which are conformal,densely packed and additive-free,can exhibit gravimetric energies up to 200W h kg electrode 21at a gravimetric power of 100kW kg electrode 21,where the gravimetric energy and power at the cell level can be estimated by dividing these values by a factor of 5.The energy stored in the LBL-MWNT electrodes can be con-trolled by the electrode thickness (Fig.3c,inset)and upper voltage limit (Supplementary Fig.S12).Redox of surface oxygen-containing functional groups on LBL-MWNT electrodes by lithium ions in organic electrolytes,which can be accessed reversibly at high power,are predominantly responsible for the observed high energy and power capabilities of LBL-MWNT electrodes,as can be seen in the high-resolution TEM (HRTEM)image of the LBL-MWNT elec-trode in Fig.5.We have demonstrated energy and power capabilities of LBL-MWNT electrodes with thicknesses of a few micrometres that will open up new opportunities in the development of high-performance electrical energy storage for microsystems,and ﬂexible,thin-ﬁlm devices 22.Further research will seek to validate the reported energy and power capabilities of MWNT electrodes with thicknesses of the order of tens and hundreds of micrometres,and minimize energy loss during charge and discharge (charging voltages of LBL-MWNT107a b cd1061054.5 V (1.48 ± 0.14 µm) at 250 mA g −1104103102G r a v i m e t r i c p o w e r (W k g −1)107106105104103102G r a v i m e t r i c p o w e r (W k g −1)Gravimetric energy (W h kg −1)101102103Gravimetric energy (W h kg −1)Q (m A h g −1)Cycle number01st cycle1,000th cycle 102030012345050100150200Q (mA h g −1)E (V v e r s u s L i )Q (µA h)Figure 4|Gravimetric energy and power densities,and cycle life of LBL-MWNT electrodes obtained from measurements of two-electrode cells.a ,Ragone plot for Li /LBL-MWNT cells with different thicknesses ( 0.3–3.0m m).The corresponding loading density of LBL-MWNT electrodes ranges from 0.025–0.25mg cm 22.Only the LBL-MWNT weight was considered in the gravimetric energy and power density calculations.b ,Gravimetric capacities of Li /LBL-MWNT cells as a function of cycle number,measured at a current density of 0.25A g 21once every 100cycles,after voltage holds at the end of charging and discharging for 30min.Within each 100cycles,these cells were cycled at an accelerated rate of 2.5A g 21.c ,Voltage proﬁles of a 1.5-m m electrode in the ﬁrst and 1,000th cycles,for which negligible changes were noted.d ,Ragone plot for Li /LBL-MWNT (black squares),L TO /LBL-MWNT (green circles),L TO /LiNi 0.5Mn 1.5O 4(grey circles)and LBL-MWNT /LBL-MWNT (orange triangles)cells with 4.5V versus Li as the upper-potential limit.The thickness of the LBL-MWNT electrode was 0.3m m for asymmetric Li /LBL-MWNT and L TO /LBL-MWNT,and 0.4m m for symmetric LBL-MWNT /LBL-MWNT.Gravimetric energy and maximum power densities were reduced for the L TO /LBL-MWNT cells subjected to the same testing conditions due to a lower cell voltage.DOI:10.1038/NNANO.2010.116electrodes are higher than those on discharge,even at low rates).Large-scale thicker electrodes of tens of micrometres can be produced using a recently developed sprayed LBL system 45that uses an auto-mated process to reduce assembly time dramatically (about 70times faster than the conventional dipping of LBL systems used in this study).Modiﬁcation of the surface functional groups on carbon 46,47may allow the tuning of redox potentials and increase efﬁciency by reducing the voltage difference during charge and discharge.MethodsMaterials.MWNTs prepared by chemical vapour deposition were purchased from NANOLAB (95%purity;outer diameter,15+5nm).Carboxylated MWNTs (MWNT–COOH)and amine-functionalized MWNTs (MWNT–NH 2)wereprepared and assembled onto ITO-coated glass slides (procedures are described in detail elsewhere 23).Cross-sectional scanning electron microscope (SEM)images of MWNT electrodes after heat treatments were obtained using a JEOL 6320SEM operated at 5kV.Fabrication of layer-by-layer MWNT electrodes.MWNT–COOH and MWNT–NH 2powder samples were sonicated for several hours in Milli-Q water (18M V cm)to form a uniform dispersion,and this was followed by dialysis using Milli-Q water for several days,resulting in a stable dispersion of functionalized MWNTs in solution (0.5mg ml 21).pH values of the solutions were adjusted to pH 2.5(MWNT–NH 2)and pH 3.5(MWNT–COOH),respectively,and the solutions were sonicated for 1h just before LBL assembly.All-MWNT electrodes were assembled with a modiﬁed Carl Zeiss DS50programmable slide stainer.Details of LBLassembly of MWNT electrodes can be found elsewhere 23.Assembled LBL-MWNT electrodes were dried in air,and these ﬁlms were then heat-treated sequentially at 1508C in vacuum for 12h,and at 3008C in H 2for 2h to increase mechanical stability.X-ray photoelectron spectroscopy (XPS).A Kratos Axis Ultra XPS instrument (Kratos Analytical)with a monochromatized Al K a X-ray source was used to analyse the surface chemistry of functionalized MWNTs and LBL-MWNTelectrodes.The take-off angle relative to the sample substrate was 908.Curve ﬁtting of the photoemission spectra was performed following a Shirley-type background subtraction.An asymmetric C 1s peak from sp 2hybridized carbons centred at 284.5eV was generated for raw ing this asymmetric peak as a reference,all other peaks were ﬁtted by the Gaussian–Lorentzian function.The experimental uncertainty of the XPS binding energy was +0.1eV.The relative sensitivity factors used to scale the peaks of C 1s ,O 1s and N 1s were 0.278,0.780and 0.477,respectively.Electrochemical measurements.Electrochemical measurements were conducted using a two-electrode electrochemical cell (Tomcell)consisting of an LBL-MWNT electrode on ITO-coated glass,two sheets of microporous membrane (Celgard 2500,Celgard)and lithium foil as the counter-electrode.LBL-MWNT electrode areas of 100or 50mm 2were used for electrochemical measurements with Li foil andlithiated LTO negative electrodes.The weights of the LBL-MWNT electrodes were determined from the area and the mass area density (see SupplementaryInformation).The loading density of the LBL-MWNT electrodes ranged from 0.025to 0.25mg cm 22.A piece of aluminium foil (25m m thick and with an areaof 1mm ×7mm in contact with the LBL-MWNT electrode)was attached to one edge and used as a current collector.The electrolyte solution was 1M LiPF 6dissolved in a mixture of ethylene carbonate (EC)and dimethyl carbonate (DMC)with a 3:7volume ratio (3.5ppm H 2O impurity,Kishida Chem.).The separators were wetted by a minimum amount of electrolyte to reduce the background current.Cyclic voltammetry and galvanostatic measurements of the lithium cells were performed using a Solartron 4170at room temperature.Received 26March 2010;accepted 13May 2010;published online 20June 2010References1.Simon,P.&Gogotsi,Y.Materials for electrochemical capacitors.Nature Mater.7,845–854(2008).ler,J.R.&Simon,P.Materials science—electrochemical capacitors forenergy management.Science 321,651–652(2008).3.Amatucci,G.G.,Badway,F.,Du Pasquier,A.&Zheng,T.An asymmetric hybridnonaqueous energy storage cell.J.Electrochem.Soc.148,A930–A939(2001).4.Kang,B.&Ceder,G.Battery materials for ultrafast charging and discharging.Nature 458,190–193(2009).5.Lee,Y.J.et al .Fabricating genetically engineered high-power lithium-ionbatteries using multiple virus genes.Science 324,1051–1055(2009).6.Nazar,L.F.et al .Nanostructured materials for energy storage.Int.J.Inorg.Mater.3,191–200(2001).7.Arico,A.S.et al .Nanostructured materials for advanced energy conversion andstorage devices.Nature Mater.4,366–377(2005).8.Poizot,P.et al .Nano-sized transition-metaloxides as negative-electrodematerials for lithium-ion batteries.Nature 407,496–499(2000).9.Sides,C.R.et al .Nanoscale materials for lithium-ion batteries.MRS Bull.27,604–607(2002).10.Bruce,P.G.,Scrosati,B.&Tarascon,J.M.Nanomaterials for rechargeablelithium batteries.Angew.Chem.Int.Ed.47,2930–2946(2008).11.Tarascon,J.M.&Armand,M.Issues and challenges facing rechargeable lithiumbatteries.Nature 414,359–367(2001).12.Armand,M.&Tarascon,J.M.Building better batteries.Nature 451,652–657(2008).13.Wu,X.L.et al .LiFePO 4nanoparticles embedded in a nanoporous carbonmatrix:superior cathode material for electrochemical energy-storage devices.Adv.Mater.21,2710–2714(2009).14.Chmiola,J.et al .Anomalous increase in carbon capacitance at pore sizes lessthan 1nanometer.Science 313,1760–1763(2006).15.Hu,C.C.,Chen,W.C.&Chang,K.H.How to achieve maximum utilization ofhydrous ruthenium oxide for supercapacitors.J.Electrochem.Soc.151,A281–A290(2004).16.Fischer,A.E.et al .Incorporation of homogeneous,nanoscale MnO 2withinultraporous carbon structures via self-limiting electroless deposition:implications for electrochemical capacitors.Nano Lett.7,281–286(2007).17.Reddy,A.L.M.,Shaijumon,M.M.,Gowda,S.R.&Ajayan,P.M.CoaxialMnO 2/carbon nanotube array electrodes for high-performance lithium batteries.Nano Lett.9,1002–1006(2009).18.Kim,D.K.et al .Spinel LiMn 2O 4nanorods as lithium ion battery cathodes.NanoLett.8,3948–3952(2008).19.Be´langer,D.,Brousse,T.&Long,J.W.Manganese oxides:battery materials make the leap to electrochemical capacitors.Electrochem.Soc.Interf.17,49–52(2008).20.Decher,G.Fuzzy nanoassemblies:toward layered polymeric multicomposites.Science 277,1232–1237(1997).21.Xiang,H.F.et al .Effect of capacity matchup in the LiNi 0.5Mn 1.5O 4/Li 4Ti 5O 12cells.J.Power Sources 183,355–360(2008).22.Dudney,J.N.Thin ﬁlm micro-batteries.Electrochem.Soc.Interf.17,44–48(2008).23.Lee,Seung Woo et al .Layer-by-layer assembly of all carbon nanotube ultrathinﬁlms for electrochemical applications.J.Am.Chem.Soc.131,671–679(2009).24.Niu,C.M.et al .High power electrochemical capacitors based on carbonnanotube electrodes.Appl.Phys.Lett.70,1480–1482(1997).25.Futaba,D.N.et al .Shape-engineerable and highly densely packed single-walledcarbon nanotubes and their application as super-capacitor electrodes.Nature Mater.5,987–994(2006).26.Zielke,U.,Huttinger,K.J.&Hoffman,W.P.Surface-oxidized carbon ﬁbers:I.Surface structure and chemistry.Carbon 34,983–998(1996).27.Kozlowski,C.&Sherwood,P.M.A.X-ray photoelectron-spectroscopic studiesof carbon-ﬁbre surfaces.Part 5.The effect of pH on surface oxidation.J.Chem.Soc.Farad.Trans.I 81,2745–2756(1985).28.Frackowiak,E.et al .Electrochemical storage of lithium multiwalled carbonnanotubes.Carbon 37,61–69(1999).29.Zhu,X.Y.,Lee,S.M.,Lee,Y.H.&Frauenheim,T.Adsorption and desorption ofan O 2molecule on carbon nanotubes.Phys.Rev.Lett.85,2757–2760(2000).30.Burg,P.et al .The characterization of nitrogen-enriched activated carbons by IR,XPS and LSER methods.Carbon 40,1521–1531(2002).Surface functional groups:Faradaic RXN centresOOLi Li Li+OO Figure 5|Schematic of the energy storage mechanism of LBL-MWNT electrodes.Faradaic reactions between surface oxygen functional species (orange arrows)and Li schematically illustrated on an HRTEM image of the LBL-MWNT electrodes.Intact graphite layers inside the MWNT s (white arrows)are indicated as electron conduction channels.DOI:10.1038/NNANO.2010.116。

iScript_cDNA_Synthesis_Kit

The maximum amount of the cDNA reaction that is recommended for downstream PCR is one-tenth of the reaction volume, typically 2µl.
*When using larger amounts of input RNA (>1µg) the reaction should be scaled up e.g. 40µl reaction for 2µg, 100µl reaction for 5µg to ensure optimum synthesis efficiency.
The iScript reverse transcriptase is RNAse H+, resulting in greater sensitivity than RNAse H- enzymes. iScript is a modified MMLV-derived reverse transcriptase, optimized for reliable cDNA synthesis over a wide dynamic range of input RNA. The enzyme is provided pre-blended with RNAse inhibitor. The unique blend of oligo (dT) and random hexamer primers in the iScript Reaction Mix works exceptionally well with a wide variety of targets. This blend is optimized for the production of targets < 1kb in length.

ARTISAN TECHNOLOGY GROUP 设备购买、维修与售卖说明书

Agilent 81689A / 81689B / 81649A Compact Tunable Laser Modules Technical SpecificationsFebruary 2002The 81689A, 81689B, 81649A compact tunable lasermodules offer superior performance now also in the compactmodule class. As they are tunable with continuous outputpower, they are the most flexible stimulus for the test ofoptical amplifiers, DWDM components as well as for the testof complete DWDM systems.Compact tunable lasers for C-and L-bandThe Agilent 81689A and 81689B modules operate in the C-band from 1525 nm to 1575 nm, whereas the Agilent 81649A covers the L-band from 1570 nm to 1620 nm.Test of optical amplifiersA variable amount of the compact, yet fully remote controlled Agilent 81689A, 81689B and 81649A tunable laser modules, in combination with the 81682A and 81642A high power Tunable Laser, is the ideal solution to characterize optical amplifiers for use in DWDM applications. The 81689A, 81689B and 81649A compact tunable laser modules provide the high stimulus power needed to test today's optical amplifiers. Together with the 81651A optical attenuator module, an output power dynamic range of more than60 dB can be achieved. Even without the attenuator module the power can be attenuated by 9dB (10dB for 81689B) e.g. to equalize power levels of several sources. Polarization Maintaining Fiber for the test of integrated optical devicesThe 81689A, 81689B and 81649A modules are ideally constructed to characterize integrated optical devices. Their optional Panda PMF output ports provide a well defined state of polarization to ensure constant measurement conditions on waveguidedevices. A PMF cable easily connectsan external optical modulator.The 81689A, 81689B and 81649A isavailable with both, standard single-mode fiber and Panda type PMF.Compact module for DWDMmulti-channel testThe 81689A, 81689B and 81489Aallow a realistic multi-channel test bedfor DWDM transmission systems to beset up.Their flexibility make them thepreferred choice for tests of DWDMtransmission system during installationand maintenance phases.Compact spare for DFBmodules in ITU gridsThe 81689B for the first time solvesthe sparing nightmare for users ofDWDM combs. In combination with acomb of 81662A DFB lasers the81689B can replace any DFB between1525nm and 1575nm without powerpenalty.Remote control & PnPsoftware drivers for easyprocess automationIts continuous, mode-hop free tuningmakes it quick and easy to set even themost complex configurations to thetarget wavelengths and power levels,just by dialing or using the vernier keys.A 8163B mainframe can host2 compact tunable laser modules. Thisallows for the most compact C- and L-band stimulus solution available today.Each 8164B mainframe can host up tofour units of the 81689A, 81689B or81649A in its upper slots.The 8166B is most interesting for highchannel count solutions. Up to17 compact tunable laser modules canbe hosted here.The 81649A, 81689A and 81689B areproduced to ISO 9001 internationalquality system standard as part ofAgilent's commitment to continuallyincreasing customer satisfactionthrough improved quality control.Specifications describe theinstrument's warranted performance.They are verified at the end of a 2 mlong patchcord and are valid afterwarm-up and for the stated outputpower and wavelength ranges.Each specification is assured bythoroughly analyzing all measurementuncertainties. Supplementaryperformance characteristics describethe instrument’s non-warranted typicalperformance.Every instrument is delivered with acommercial certificate of calibrationand a detailed test report.For further details on specifications,see the Definition of Terms in AppendixC of the Compact Tunable Laser User'sGuide.81689A, 81689B, 81649A Compact Tunable Laser for Multi-channel test applicationsAgilent 81689A Agilent 81689B Agilent 81649A Wavelength range1525 nm to 1575 nm1525 nm to 1575 nm1570 nm to 1620 nm Wavelength resolution0.01 nm, 1.25 GHz at 1550 nm0.01 nm, 1.25 GHz at 1550 nm0.01 nm, 1.17 GHz at 1595 nm Absolute wavelength accuracy (typ.) [1]±0.3 nm±0.3 nm±0.3 nmRelative wavelength accuracy [1]±0.3 nm±0.15 nm±0.15 nmWavelength repeatability [1]±0.05 nm±0.05 nm±0.05 nmWavelength stability(typ., over 24 h at constant temperature)[1] (typ., over 1 h at constant temperature)[1]±0.02 nm±0.01 nm±0.005 nm±0.01 nm±0.005 nmTuning speed (typ.)<10 sec/ 50 nm<10 sec/ 50 nm<10 sec/ 50 nmLinewidth (typ.) [2]with Coherence Control ON (typ.) [2]20 MHz---< 20MHz>100MHz< 20MHz>100MHzOutput power (continuous power on duringtuning)≥ 6 dBm (1525 –1575nm)≥ 10 dBm (1525 –1575nm)≥ 6 dBm (1570 –1620nm) Minimum output power–3 dBm0 dBm–3 dBmPower stability (at constant temperature) [3]±0.03 dB over 1 hour,typ. ±0.06 dB over 24 hours ±0.015 dB over 1 hour,typ. ±0.0075 dB over 1 hour,typ. ±0.05 dB over 24 hours±0.015 dB over 1 hour,typ. ±0.0075 dB over 1 hour,typ. ±0.05 dB over 24 hoursPower repeatability (typ.) [3]±0.02 dB±0.02 dB±0.02 dB Power linearity±0.1dB±0.1dB±0.1dB Power flatness versus wavelength±0.3 dB±0.2 dB±0.2 dBSide-mode suppression ratio (typ.) [2]> 40 dB(1525 – 1575 nm at 0 dBm)> 45 dB(1525 – 1575 nm at ≥ 3 dBm)> 45 dB(1570 – 1620 nm at ≥ 0 dBm)Signal to source spontaneous emission ratio (typ.) [4]≥ 39 dB/ nm(1525 –1575 nm at 6 dBm)≥ 44 dB/ nm(1525 –1575 nm at 10 dBm)≥ 42 dB/ nm(1570 – 1620 nm at 6 dBm)Relative intensity noise (RIN, typ.)< -137 dB/Hz(100 MHz – 2.5 GHz, at +3 dBm)< -137 dB/Hz(100 MHz – 2.5 GHz, at +7 dBm)< -137 dB/Hz(100 MHz – 2.5 GHz, at +3 dBm)Dimensions75 mm H, 32 mm W, 335 mm D(2.8" x 1.3" x 13.2")75 mm H, 32 mm W, 335 mm D(2.8" x 1.3" x 13.2")75 mm H, 32 mm W, 335 mm D(2.8" x 1.3" x 13.2")Weight 1 kg 1 kg 1 kg[1]At CW operation. Measured with wavelength meter based on wavelength in vacuum.[2]Measured by heterodyning method.[3]500 ms after changing power.[4]Measured with optical spectrum analyzer at 1 nm resolution bandwidth.Listed optionsOption 021: standard single mode fiber,straight contact output connectorOption 022: standard single mode fiber,angled contact output connectorOption 071: polarization maintainingfiber, straight contact output connectorOption 072: polarization maintainingfiber, angled contact output connectorSupplementary performance characteristics ModulationInternal digital modulation50% duty cycle, 200 Hz to 300 kHz.>45% duty cycle, 300 kHz to 1 MHz. Modulation output (via Mainframe): TTL reference signal.External digital modulation> 45% duty cycle, fall time< 300 ns, 200 Hz to 1 MHz. Modulation input (via Mainframe):TTL signal.External analog modulation≥ ±15% modulation depth,5 kHz to 1 MHz.Modulation input: 5 Vp-p Coherence control(81649A/81689B)For measurements on components with 2 m long patchcords and connectors with 14 dB return loss, the effective linewidth results in a typical power stability of< ±0.025 dB over1 minute by reducing interference effects in the test setup.GeneralOutput isolation (typ.):38 dBReturn loss (typ.):55 dB (options 022, 072)40 dB (options 021, 071)Polarization maintaining fiber (Options071, 072)Fiber type: Panda.Orientation: TE mode in slow axis,in line with connector key.Extinction ratio: 16 dB typ.Laser class:Class IIIb according to FDA 21 CFR1040.10, Class 3A according to IEC 825- 1; 1993.Recommended re-calibration period:2 years.Warm-up time:< 40 min,immediate operation after boot-up.EnvironmentalStorage temperature:–20 °C to +70 °C (81689A)–40 °C to +70 °C (81689B, 81649A)Operating temperature:15 °C to 35 °CHumidity:< 80 % R.H. at 15 °C to 35 °CSpecifications are valid in non-condensingconditions.Laser Safety InformationAll laser sources specified by this datasheet are classified as Class 1Maccording to IEC 60825-1 (2001).All laser sources comply with 21 CFR1040.10 except for deviations pursuantto Laser Notice No. 50, dated 2001-July-26This page intentially left blankAgilent Technologies’Test and Measurement Support,Services, and AssistanceAgilent Technologies aims to maximize the value you receive, while minimizing your risk and problems. We strive to ensure that you get the test and measurement capabilities you paid for and obtain the support you need. Our extensive support resources and services can help you choose the right Agilent products for your applications and apply them successfully. Every instrument and system we sell has a global warranty. Support is available for at least five years beyond the production life of the product. Two concepts underlie Agilent's overall support policy: "Our Promise" and "Your Advantage."Our PromiseOur Promise means your Agilent test and measurement equipment will meet its advertised performance and functionality. When you are choosing new equipment, we will help you with product information, including realistic performance specifications and practical recommendations from experienced test engineers. When you use Agilent equipment, we can verify that it works properly, help with product operation, and provide basic measurement assistance for the use of specified capabilities, at no extra cost upon request. Many self-help tools are available.Your AdvantageYour Advantage means that Agilent offers a wide range of additional expert test and measurement services, which you can purchase according to your unique technical and business needs. Solve problems efficiently and gain a competitive edge by contracting with us for calibration, extra-cost upgrades, out-of-warranty repairs, and on-site education and training, as well as design, system integration, project management, and other professional engineering services. Experienced Agilent engineers and technicians worldwide can help you maximize your productivity, optimize the return on investment of your Agilent instruments and systems, and obtain dependable measurement accuracy for the life of those products.By internet, phone, or fax, get assistance with all your test & measurement needsOnline assistance:Related Agilent Literature:/coms/lightwaveAgilent 8163A Lightwave MultimeterPhone or Fax Agilent 8164A Lightwave Measurement SystemUnited States:Agilent 8166A Lightwave Multichannel System(tel)180****4844Technical Specificationsp/n 5988-1568ENCanada:(tel)187****4414Agilent 81662A DFB Laser(fax) (905) 206 4120Agilent 81663A DFB LaserAgilent Fabry Perot LaserTechnical SpecificationsEurope:p/n 5988-1570EN(tel) (31 20) 547 2323(fax) (31 20) 547 2390Agilent Power Sensor ModulesJapan:Agilent Optical Heads(tel) (81) 426 56 7832Agilent Return Loss Modules(fax) (81) 426 56 7840Technical Specificationsp/n 5988-1569ENLatin America:(tel) (305) 269 7500(fax) (305) 269 7599Agilent 8163A/B Lightwave MultimeterAgilent 8164A/B Lightwave Measurement SystemAustralia:Agilent 8166A/B Lightwave Multichannel System(tel) 1 800 629 485 Configuration Guide(fax) (61 3) 9210 5947p/n 5988-1571ENNew Zealand:Agilent 8163B Lightwave Multimeter(tel) 0 800 738 378Agilent 8164B Lightwave Measurement System(fax) 64 4 495 8950Agilent 8166B Lightwave Multichannel SystemTechnical SpecificationsAsia Pacific:p/n 5988-3924EN(tel) (852) 3197 7777(fax) (852) 2506 9284Product specifications and descriptions in this document subject to change without notice.Copyright © 2001 Agilent TechnologiesFebruary 12 20025988-3675EN。

伯乐生化质控靶值表310

oset0europe15胆碱酯酶umollsec8426674101315252378胆碱酯酶umollsec985789118370296443creatinekinasecknacactivatedeuropeasia5肌酸激酶umollsec215172258704563845creatinekinaseckrosalkiothermodied5肌酸激酶umollsec212169254713570855creatinealkalinepicratekineticcartridgecrsumoll188150225510408612creatinealkalinepicratekineticmodularcre3creatineenzymaticcredigoxinimmunoturbidimetric地高辛nmoll107339271407gammaglutamyltransferaseggtszasz5谷氨酰转肽酶umollsec0927249gammaglutamyltransferaseggtszaszifcc20025谷氨酰转肽酶umollsec1070853128257206309glucoseglucoseoxidaseoxygenconsumptionglu3葡萄糖mmoll462148glucosehexokinase0glu葡萄糖mmoll493394591155ironferrozinenodeproteinizationumoll428118lactatelacticacidenzymatic乳酸umolllactatedehydrogenaseldhlactatepyruvate5乳酸脱氢酶umollsec234281281502401602lactatedehydrogenaseldhlactatepyruvateifcc20025乳酸脱氢酶umollsec291611489733lipasecolorimetriclip5脂肪酶umollsec0590154magnesiumcalmagitemmoll0830163phenobarbitalimmunoturbidimetric苯巴比妥umollphenytoinimmunoturbidimetricumoll423865phosphorusphosphomolybdateuvcartridgepo4mmoll115240p

安捷伦产品目录

15
Real-Time PCR
16
Mx3000P QPCR System
17
Brilliant III Ultra-Fast SYBR Green QPCR and QRT-PCR Reagents
18
Brilliant III Ultra-Fast QPCR and QRT-PCR Reagents
Agilent / STRATAGENE
Agilent website: /genomics
Welgene | Agilent Stratagene
威健股份有限公司 | Stratagene 總代理
Table of Content
Table of Contents
/ XL1-Red Competent Cells SoloPack Gold Supercompetent Cells
/ TK Competent Cells Specialty Cells
/ Classic Cells / Fine Chemicals For Competent Cells
適用於 UNG 去汙染或 bisulphite
sequencing
適用於 TA Cloning
最高敏感性
取代傳統 Taq 的好選擇
-
2
威健股份有限公司 | Stratagene 總代理
PCR Enzyme & Instrument
Agilent SureCycler 8800
市場上領先的 cycling 速度和 sample 體積 10 ～ 100 μL 簡易快速可以選擇 96 well 和 384 well 操作盤優秀的溫控設備讓各個 well 都能保持溫度的穩定七吋的高解析度觸控螢幕讓操作上更為簡便可以透過網路遠端操控儀器及監控儀器 Agilent 專業的技術支援可以幫助您應對各種 PCR 的問題

重组贻贝粘蛋白的表征及功效评价

生物技术进展 2023 年第 13 卷第 4 期 596 ~ 603Current Biotechnology ISSN 2095‑2341研究论文Articles重组贻贝粘蛋白的表征及功效评价李敏，魏文培，乔莎，郝东，周浩，赵硕文，张立峰，侯增淼 *西安德诺海思医疗科技有限公司，西安 710000摘要：为了推进重组贻贝粘蛋白在医疗、化妆品领域的应用，对大肠杆菌规模化发酵及纯化生产获得的重组贻贝粘蛋白进行了表征及功效评价。

经Edman 降解法、基质辅助激光解吸电离飞行时间质谱、PITC 法、非还原型SDS -聚丙烯酰胺凝胶电泳法、凝胶法、改良的Arnow 法对重组贻贝粘蛋白进行氨基酸N 端测序、相对分子量分析、氨基酸组成分析、蛋白纯度分析、内毒素含量测定、多巴含量测定；通过细胞迁移、斑马鱼尾鳍修复效果对重组贻贝粘蛋白进行功效评价。

结果显示，获得的重组贻贝粘蛋白与理论的一级结构一致，蛋白纯度达95%以上，内毒素<10 EU ·mg -1,多巴含量大于5%；重组贻贝粘蛋白浓度为60 μg ·mL -1时能够显著促进细胞增殖的活性（P <0.01）；斑马鱼尾鳍面积样品组与模型对照组相比极显著增加（P <0.001）。

研究结果表明，重组贻贝粘蛋白具有显著的促细胞迁移和修复愈合的功效，具备作为生物医学材料的潜质。

关键词：贻贝粘蛋白；基因重组；生物材料；表征；功效评价DOI ：10.19586/j.20952341.2023.0021 中图分类号：S985.3+1 文献标志码：ACharacterization and Efficacy Evaluation of Recombinant Mussel Adhesive ProteinLI Min ， WEI Wenpei ， QIAO Sha ， HAO Dong ， ZHOU Hao ， ZHAO Shuowen ， ZHANG Lifeng ，HOU Zengmiao *Xi'an DeNovo Hith Medical Technology Co.， Ltd ， Xi'an 710000， ChinaAbstract ：In order to promote the application of recombinant mussel adhesive protein in the medical and cosmetics field ， the recombi⁃nant mussel adhesive protein obtained from scale fermentation and purification of Escherichia coli was characterized and its efficacy was evaluated. Amino acid N -terminal sequencing ， relative molecular weight analysis ， amino acid composition analysis ， protein purityanalysis ， endotoxin content ， dihydroxyphenylalanine （DOPA ） content of recombinant mussel adhesive protein were determined by the following methods ： Edman degradation ， matrix -assisted laser desorption ionization time -of -flight mass spectrometry （MALDI -TOF -MS ）， phenyl -isothiocyanate （PITC ）， nonreductive SDS -polyacrylamide gel electrophoresis （SDS -PAGE ）， gel method ， modified Ar⁃now. The efficacy of recombinant mussel adhesive protein was evaluated by cell migration and repairing effect of zebrafish tail fin. Re⁃sults showed that the obtained recombinant mussel adhesive protein was confirmed to be consistent with the theoretical primary structure ， protein purity of more than 95%， endotoxin <10 EU ·mg -1， DOPA content above 5%. When the recombinant mussel adhesive protein concentration was 60 μg ·mL -1， the effect of promoting cell proliferation was the most obvious ， and it had very significant activity （P <0.01）. The caudal fin area of zebrafish in sample group was significantly increased compared with model control group （P <0.001）. The results indicated that recombinant mussel adhesive protein can promote cell migration and repair healing and has the potential to be used as biomedical materials.Key words ：mussel adhesive protein ； gene recombination ； biological materials ； representation ； efficacy evaluation贻贝粘蛋白（mussel adhesive protein ， MAP ）也称作贻贝足丝蛋白（mussel foot protein ，Mfps ），收稿日期：2023⁃02⁃24；接受日期：2023⁃03⁃31联系方式：李敏 E -mail:*******************;*通信作者侯增淼 E -mail:***********************.cn李敏，等：重组贻贝粘蛋白的表征及功效评价是海洋贝类——紫贻贝（Mytilus galloprovincalis）、厚壳贻贝（Mytilus coruscus）、翡翠贻贝（Perna viri⁃dis）等分泌的一种特殊的蛋白质，贻贝中含有多种贻贝粘蛋白，包括贻贝粘蛋白（Mfp 1～6）、前胶原蛋白（precollagens）和基质蛋白（matrix proteins）等［1］。

GNE-477-SDS-MedChemExpress

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Oct.-01-2018Print Date:Oct.-01-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :GNE-477Catalog No. :HY-11042CAS No. :1032754-81-61.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:GNE477;GNE 477Formula:C21H28N8O3S2Molecular Weight:504.63CAS No. :1032754-81-64. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

IFCC Aspartate Aminotransferase 检测手册说明书

ASTAspartate Aminotransferase IFCCMANUAL RX MONZAINTENDED USEFor the quantitative in vitro determination of AspartateAminotransferase (AST) in serum and plasma. This product is suitable for manual use and on the Rx Monza analyser.Cat. No. AS 1202 R1a. Buffer/Substrate 1 x 70 ml 20 x 2 ml R1b. Enzyme/Coenzyme/ 20 x 2 ml α-oxoglutarate GTIN: 05055273200416AS 1204 R1a. Buffer/Substrate 1 x 105 ml 10 x 10 ml R1b. Enzyme/Coenzyme/ 10 x 10 ml α-oxoglutarate GTIN: 05055273200423AS 1267 R1a. Buffer/Substrate 1 x 105 ml 5 x 20 ml R1b. Enzyme/Coenzyme/ 5 x 20 ml α-oxoglutarate GTIN: 05055273200430AS 2359 R1a. Buffer/Substrate 5 x 100 ml 5 x 100 ml R1b. Enzyme/Coenzyme/ 5 x 100 ml α-oxoglutarate GTIN: 05055273200454UV METHODThis is an optimised standard method according to the concentrations recommended by the IFCC.CLINICAL SIGNIFICANCE (1,2,3,4)The aminotransferases are a group of enzymes that catalyse the inter conversions of amino acids and α-oxoacids by transfer of amino groups. AST (aspartate aminotransferase or glutamate oxaloacetatetransaminase) has been found in the cytoplasm and the mitochondria of cells that have been studied. In cases of mild tissue damage, e.g. liver, the predominant form of serum AST is that from the cytoplasm, with a smaller amount coming from the mitochondria. Severe tissue damage will result in more mitochondrial enzyme being released. Elevated levels of AST can signal myocardial infarction, hepatic disease, muscular dystrophy and organ damage.Although heart muscle is found to have the most activity of the enzyme, significant activity has also been seen in the brain, liver, gastric mucosa, adipose tissue and kidneys of humans.The IFCC has now recommended (1980) standardised procedures for AST determinations including:-1. optimization of substrate concentrations.2. Employment of Tris buffers (instead of phosphate, which has beenshown to inhibit recombination of the apoenzyme with pyridoxal phosphate).3. Pre-incubation of combined buffer and serum to allow sidereactions with NADH to occur. 4. Substrate start (α-oxoglutarate)5. Optional pyridoxal phosphate activation.This is an optimised standard method according to the recommendations of the IFCC.PRINCIPLEα-oxoglutarate reacts with L-aspartate in the presence of AST to form L-glutamate plus oxaloacetate. The indicator reaction utilises the oxaloacetate for a kinetic determination of NADH consumption. AST -oxoglutarate + L-aspartate L-glutamate + oxaloacetate MDH oxaloacetate + NADH + H + L-malate + NAD +SPECIMEN COLLECTION AND PREPARATION (5) Serum:- Use serum free from haemolysis.Plasma:- EDTA or heparin can be used as the anticoagulant.Plasma should be separated from cells within one hour after collection.Specimens should be refrigerated if not used immediately:-Specimens stored longer than 3 days should be frozen at -20︒C.REAGENT COMPOSITIONContents Concentrations in the TestR1a. Buffer/Substrate Tris buffer 80 mmol/l, pH 7.5 L-aspartate 240 mmol/l R1b. Enzyme/Coenzyme/α-oxoglutarate α-oxoglutarate 12 mmol/l MDH ≥420 U/l LD ≥600 U/l NADH 0.18 mmol/lSAFETY PRECAUTIONS AND WARNINGS For in vitro diagnostic use only. Do not pipette by mouth.Exercise the normal precautions required for handling laboratory reagents.Solution R1a contains Sodium Azide. Avoid ingestion or contact with skin or mucous membranes. In case of skin contact, flush affected area with copious amounts of water. In case of contact with eyes or if ingested, seek immediate medical attention.Sodium Azide reacts with lead and copper plumbing, to form potentially explosive azides. When disposing of such reagents flush with large volumes of water to prevent azide build up. Exposed metal surfaces should be cleaned with 10% sodium hydroxide.Health and Safety data sheets available on request.The reagents must be used only for the purpose intended by suitably qualified laboratory personnel, under appropriate laboratory conditions.STABILITY AND PREPARATION OF REAGENTS R1a. Buffer/SubstrateContents ready for use. Stable up to the expiry date when stored at +2 to +8︒C.R1b. Enzyme/Coenzyme/α-oxoglutarate Reconstitute one vial of Enzyme/Coenzyme/α-oxoglutarate R1b with the appropriate volume of Buffer/Substrate R1a: 2 ml for the 20 x 2 ml kit (AS 1202) 10 ml for the 10 x 10 ml kit (AS 1204) 20 ml for the 5 x 20 ml kit (AS 1267) Stable for 14 days at +2 to +8︒C or 24 hours at +15 to +25︒C. Cat. AS 2359 5 x 100 mlReconstitute one vial of Enzyme/Coenzyme/α-oxoglutarate R1b with a portion of Buffer/Substrate R1a and then transfer the entire contents to bottle R1a rinsing bottle R1b several times. Stable for 14 days at +2 to +8︒C or 24 hours at +15 to +25︒C.MATERIALS PROVIDED Buffer/SubstrateEnzyme/Coenzyme/ -oxoglutarateMATERIALS REQUIRED BUT NOT PROVIDEDRandox Assayed Multisera Level 2 (Cat. No. HN 1530) and Level 3 (Cat. No. HE 1532)Randox Calibration Serum Level 3 (Cat. No. CAL 2351) RX series Saline (Cat. No. SA 3854)PROCEDUREAspirate fresh ddH 2O and perform a new Gain Calibration in flow cell mode. Select AST in the Run Test screen and carry out a water blank as instructed.Pipette into a test tube:Sample 0.05 ml Reagent 0.5 mlMix and aspirate into the Rx Monza.CALIBRATION FOR RX MONZAThe use of Saline and Randox Calibration Serum Level 3 isrecommended for calibration. Calibration is recommended with change of reagent lot or as indicated by quality control procedures.FOR MANUAL USEWavelength: 340 nm (Hg 334 nm or Hg 365 nm) Cuvette: 1 cm light path Temperature: 25/30/37︒C Measurement: against airPipette into cuvette: Macro MicroSample 0.2 ml 0.1 ml Enzyme/Coenzyme/ α-oxoglutarate R1 2.0 ml 1.0 mlMix, read initial absorbance after 1 minute. Read again after 1, 2 and 3 minutes. Note: If the absorbance change per minute is between 0.11 and 0.16 at 340/Hg 334 nm 0.06 and 0.08 at Hg 365 nmuse only the values for the first 2 minutes for the calculation.MANUAL CALCULATIONTo calculate the AST activity, use the following formulae:U/l = 1746 x A 340 nm/min U/l = 1780 x A Hg 334 nm/min U/l = 3235 x A Hg 365 nm/minSTANDARDISATIONRandox Calibration Serum Level 3 is traceable to AST reference material JSCC TS01.QUALITY CONTROLRandox Assayed Multisera, Level 2 and Level 3 are recommended for daily quality control. Two levels of controls should be assayed at least once a day. Values obtained should fall within a specified range. If these values fall outside the range and repetition excludes error the following steps should be taken:1. Check instrument settings and light source.2. Check cleanliness of all equipment in use.3. Check water. Contaminants, i.e. bacterial growth, maycontribute to inaccurate results. 4. Check reaction temperature.5. Check expiry date of kit and contents.6. Contact Randox Laboratories Customer Technical Services, Northern Ireland +44 (0) 28 9445 1070.SPECIFICITY/INTERFERENCE (6,7)Gross haemolysis will produce falsely elevated test results. The effects of various drugs on AST activity should be taken intoconsideration in the case of patients receiving large doses of drugs.The analytes below were tested up to the following levels and were found not to interfere: Haemoglobin 250 mg/dl Free Bilirubin 25 mg/dl Conjugate Bilirubin 25 mg/dl Triglycerides 1000 mg/dlIntralipid ® 200 mg/dlA list of substances and conditions known to effect AST activity in vivo is given by both Young et al and Friedman et al. Norepresentation is made by Randox Laboratories Ltd regarding the completeness of these lists and the accuracy of the information contained therein.NORMAL VALUES IN SERUM (8,9) +25︒C +30︒C +37︒C Men up to 18 U/l up to 25 U/l up to 37 U/l Women up to 15 U/l up to 21 U/l up to 31 U/lIt is recommended that each laboratory establish its own reference range to reflect the age, sex, diet and geographical location of the population.SPECIFIC PERFORMANCE CHARACTERISTICS The following performance data were obtained using an Rx Monza analyser running at +37o C.LINEARITYThis method is linear up to 562 U/l. If the sample concentration exceeds this value, dilute the sample 1+9 with 0.9% NaCl solution and re-assay. Multiply the result by 10.SENSITIVITYThe minimum detectable concentration of AST with an acceptable level of precision was determined as 9.3 U/l.PRECISIONIntra AssayLevel 2 Level 3Mean (U/l) 35.6 153SD 1.66 1.47CV(%) 4.65 0.96n 20 20Inter AssayLevel 2 Level 3Mean (U/l) 35.6 153SD 1.77 7.10CV(%) 4.96 4.63n 20 20CORRELATIONThis method (Y) was compared with another commerciallyavailable method (X) and the following linear regression equationobtained:Y = 1.07X + 4.9and a correlation coefficient of r = 0.997543 patient samples were analysed spanning the range 28 to 559U/l.REFERENCES1. Wroblewski F, La Due J.S: Ann Intern Med. 1956; 45: 801.2. Wroblewski F, La Due J.S: Proc Soc Exp Biol Med 1956;91: 569.3. Bergmeyer HU, Bowers GN Jr, et al: Clin Chem 1977; 23:887.4. Bergmeyer HU, Bowers GN Jr, et al: J.Clin Chem ClinBiochem 1980; 18: 521-534.5. Tietz N W: Fundamentals of Clinical Chemistry ed 3.Philadelphia, WB Saunders Co. 1987, pg 372.6. Young D S, et al: Clin Chem 1975, 21; No5.7. Friedman RB, et al: Clin Chem 1980, 26; No4.8. Wallnofer H, Schmidt.E, Schmidt FW, eds: Synopsis derLeberkrankheiten Stuttgart, Georg Thieme Verlag, 1974.9. Thefeld W, et al: Dtsch Med Wschr 1974; 99: 343.Revised 26 Apr 16 biRev. 003THIS PAGE IS INTENTIONALLY BLANK。

Micro Motion R-Series 流量计技术说明说明书

Product Data SheetPS-00363, Rev. BMarch 2004Micro Motion® R-Series Mass and Volume Flowmeter With MVD™ T echnologyMicro MotionMicro Motion® R-Series FlowmetersWelcome to a new era in measurement technology! Now you can afford toreplace your old volumetric technology with Micro Motion® R-Series flowmeters. Micro MotionR-Series flowmeters are competitive in both price and accuracy specifications with positive displacement, differential pressure, magnetic, and vortex flowmeters, yet they have many advantages that other technologies do not have. Micro Motion R-Series flowmeters offer highly accurate flow measurement for virtually any process fluid — be it clean or not. The same flowmeter can provide direct mass and volume flow for liquids, gases, and slurries without having to be recalibrated. Their immunity to flow profile means that you can install Micro Motion R-Series flowmeters anywhere in your process without having to worry about expensive straight runs or flow straightening devices. This translates to real savings in installation and engineering costs.For general purpose flow measurement applications, Micro Motion R-Series flowmeters provide an ideal alternative to other flowmetering technologies. Micro Motion flowmeters have no moving parts — saving you money over the course of their lifetime by helping you make the best use of your time, people, and material. Micro Motion R-Series flowmeters feature integral transmitters, making them easy to install. With the new MVD™ Technology, you can also remotely mount your transmitter up to 1000 feet away using standard 4-wire cable. Y ou get the flexibility you need to mount the sensor anywhere in your process piping while saving installation costs.Micro Motion R-Series flowmeters are available to support several digital communication protocols, including HART®, Modbus®, F OUNDATION™fieldbus, and Profibus-P A. Other features include a variety of standard process connections, milliampere and pulse outputs, a standard display, and a built-in totalizer that can be reset from the display.Micro Motion R-Series flowmeters are designed to perform in harsh operating environments, and carry hazardous area approvals for the U.S.A., Canada, Europe, Japan, and other areas around the world.Micro Motion is well known for increasing plant efficiency, product quality, and profitability. Now, Micro Motion R-Series flowmeters offer all this andmore.2Micro Motion® R-Series FlowmeterBenefits of Micro Motion R-Series FlowmetersEasy to useMicro Motion R-Series flowmeters are easy to start up, have no moving parts, don’t need periodic recalibration, are non-intrusive, and don’t require regular maintenance.Reliable and ruggedThere’s nothing to wear out or break down — more than 400,000 Micro Motion flowmeters are installed and working in processes just like yours. The accumulated knowledge of Micro Motion is built into each flowmeter.Easy to installMicro Motion R-Series flowmeters require no special mounting, no straight run requirements and no flow conditioning elements.Direct mass or volume measurementWith direct mass measurement, Micro MotionR-Series flowmeters are immune to variations in pressure, temperature or process fluids. The same flowmeter can measure liquids, gases, or slurries.Greater accuracyAccuracy to 0.5% on liquids and 0.75% on gases means better product quality and less waste.Micro Motion® R-Series Flowmeter34Micro Motion ® R-Series FlowmeterLiquid flow performanceMass Volume (1)(1)The volumetric flow rate is based on a process-fluid density of 1 g/cc. For fluids with density other than 1g/cc, the maximumvolume flow rate equals the mass flow rate divided by the fluid’s density.lb/minkg/hr gal/min l/hr Nominal flow range (2)(2)Micro Motion has adopted the terminology “nominal flow range.” The upper limit of this range is the flow rate at which water atreference conditions causes approximately 15 psi (1 bar) of pressure drop for Micro Motion R-Series flowmeters.R025S, R025P 0 to 500 to 13600 to 60 to 1360R050S 0 to 1500 to 40800 to 180 to 4080R100S 0 to 6000 to 16,3250 to 720 to 16,325R200S 0 to 16000 to 43,5500 to 1920 to 43,550Maximum flow rateR025S, R025P 1002720122720R050S 3008160368160R100S 120032,65014432,650R200S320087,10038487,100Accuracy (3)(3)Flow accuracy includes the combined effects of repeatability, linearity, and hysteresis. All specifications for liquids are based onreference conditions of water at 68 to 77 °F (20 to 25 °C) and 15 to 30 psig (1 to 2 bar), unless otherwise noted.T ransmitter with MVD T echnology ±0.5% of rate (4)IFT9703 transmitterRepeatabilityT ransmitter with MVD T echnology ±0.25% of rate (4)(4)When , then andIFT9703 transmitterlb/minkg/hr gal/min l/hr Zero stabilityR025, R025P 0.010.270.00180.27R050S 0.030.820.00540.82R100S 0.12 3.270.0216 3.27R200S0.328.710.05768.710.5% of rate zero stabilityflow rate -------------------------------- 100×% of rate±±flow rate zero stability 0.005--------------------------------<accuracy zero stabilityflow rate --------------------------------100×% of rate ±=repeatability ½zero stabilityflow rate --------------------------------100×% of rate.±=0.25% of rate ½zero stabilityflow rate --------------------------------100×% of rate±±Micro Motion ® R-Series Flowmeter 5Liquid flow performance continuedTypical accuracy, turndown, and pressure drop with Series 1000 transmitterT o determine accuracy, turndown, and pressure drop with your process variables, use Micro Motion’s product selector, available at .Turndown20:110:11:1Accuracy, ± %0.500.500.50Pressure droppsi 0.10.314.2bar0.010.020.98A c c u r a c y , %, s t a n d a r d s e n s o r sNominal flow rate, %6Micro Motion ® R-Series FlowmeterGas flow performanceWhen selecting sensors for gas applications, measurement accuracy is a function of fluid mass flow rate independent of operating temperature, pressure, or composition. However, pressure drop through the sensor is dependent upon operating temperature, pressure, and fluid composition. Therefore, when selecting a sensor for any particular gas application, it is highly recommended that each sensor be sized using Micro Motion’s product selector, available at .Mass Volume (1)(1)Standard (SCFM) reference conditions are 14.7 psia and 68 °F . Normal (Nm 3/hr) reference conditions are 1.013 bar and 0 °C.lb/minkg/hrSCFMNm 3/hrTypical flow rates that produce approximately 10 psid (0.68 bar) pressure drop on air at 68 °F (20 °C) and 100 psi (6.8bar)R025S, R025P 41165790R050S 133********R100S 5013666671055R200SNot yet rated for gas.Typical flow rates that produce approximately 50 psid (3.4 bar) pressure drop on natural gas (MW 16.675) at 68 °F (20°C) and 500 psi (34 bar)R025S, R025P 16445378598R050S 49135811541825R100S 189********6936R200SNot yet rated for gas.Accuracy (2)(2)Flow accuracy includes the combined effects of repeatability, linearity, and hysteresis.T ransmitter with MVD T echnology ±0.75% of rate (3)(3)When , then andIFT9703 transmitterRepeatability (2)T ransmitter with MVD T echnology ±0.5% of rate (3)IFT9703 transmitterlb/minkg/hrZero stabilityR025S, R025P 0.010.27R050S 0.030.82R100S 0.12 3.27R200SNot yet rated for gas.flow rate zero stability 0.0075--------------------------------<accuracy zero stabilityflow rate -------------------------------- 100×% of rate ±=repeatability zero stabilityflow rate --------------------------------100×% of rate.±= 1.0% of rate zero stabilityflow rate -------------------------------- 100×% of rate±±0.5% of rate zero stabilityflow rate --------------------------------100×% of rate±±Micro Motion ® R-Series Flowmeter 7Gas flow performance continuedTypical accuracy and pressure drop with R100S with MVD Technology Air at 68 °F (20 °C), static pressures as indicated on graphNatural gas (MW 16.675) at 68 °F (20 °C), static pressures as indicated on graphInches 0lb/minkg/hr Flow rateA c c u r a c y (± % o f r a t e )psibar Inches H 20lb/min kg/hr Flow rateA c c u r a c y (± % o f r a t e )8Micro Motion ® R-Series FlowmeterTemperature limitsPressure ratingsProcess fluidSensor with extended core processor –60 to +300 °F (–50 to +150 °C)Sensor with integral IFT9703 transmitter –40 to +257 °F (–40 to +125 °C)All other models–60 to +257 °F (–50 to +125 °C)Ambient temperatureStorage (1)(1)For Series 1000/2000 transmitters, display responsiveness can decrease and display may become difficult to read below–4 °F (–20 °C). Above 131 °F (55 °C) some darkening of the display may occur.–40 to +185 °F (–40 to +85 °C) with IFT9703 transmitter, no display –40 to +140 °F (–40 to +60 °C) with Model 1700 transmitter Operation (1)–22 to +131 °F (–30 to +55 °C) with IFT9703 transmitter, no display +32 to +131 °F (0 to +55 °C) with IFT9703 transmitter and display –40 to +140 °F (–40 to +60 °C) with Model 1700 transmitter°F°C Approved temperatureULWith integral IFT9703–4 to +104–20 to +40With core processor or integral Model 1700–40 to +104–40 to +40CSAWith integral IFT9703Maximum +140Maximum +60With core processor or integral Model 1700–40 to +140–40 to +60A TEXRefer to graphs on page 9Refer to graphs on page 9Flow tube rating (1)(1)Over the entire temperature range, according to ASME B31.3.R025P2300 psi 158 bar All other models1450 psi100 barPED compliance Sensors comply with council directive 97/23/EC of 29 May 1997 on Pressure Equipment.Housing ratingAll modelsHousing is not rated for pressure containment.Micro Motion ® R-Series Flowmeter 9Hazardous area classificationsUL is a U.S.A. approvals agency. CSA is a Canadian approvals agency that provides approvals accepted both in the U.S.A. (C-US) and in Canada. A TEX is a European directive.UL and CSA (1)(1)For temperature limits, see page 8.Sensor with integrally mounted IFT9703 transmitterClass I, Div. 2, Groups A, B, C, and D Class II, Div. 2, Groups F and GSensor with integrallymounted Model 1700/2700 transmitter, or with coreprocessor Class I, Div. 1, Groups C and D Class I, Div. 2, Groups A, B, C, and D Class II, Div. 1, Groups E, F , and GATEXSensor with integrallymounted Model 1700/2700 transmitter, or with core processorSensor fluid temperature (°C)Sensor fluid temperature (°C)M a x . a m b i e n t t e m p e r a t u r e (°C )10Micro Motion ® R-Series FlowmeterMaterials of constructionWeightWetted parts (1)(1)General corrosion guides do not account for cyclical stress, and therefore should not be relied upon when choosing a wettedmaterial for your Micro Motion flowmeter. Please refer to Micro Motion’s corrosion guide for material compatibility information.316L stainless steel HousingSensor 304L stainless steelCore processor CF-3M stainless steel or epoxy-painted aluminum; NEMA 4X (IP65)Integrally mounted transmitterEpoxy-painted aluminum; NEMA 4X (IP65)Weights provided are the weight of the flowmeter with ANSI 150 lb weld neck raised face flanges.lbkg Sensor with integrally mounted IFT9703 transmitterR025157R050178R1002612R2004822Sensor with integrally mounted Model 1700/2700 transmitterR025168R050178R1002712R2004822Sensor with core processorR025168R050178R1002712R2004822Sensor with extended core processorR025176R050187R1002811R2004921Micro Motion ® R-Series Flowmeter 11DimensionsSensor with integrally mounted Model 1700 transmitterinches(mm)Dimensions inNPT female CAJON fitting dimensionsR0251 3/4(45)1 15/16(49)″–14 NPT female fitting ″–14 NPT female fittingDimensions (1)Model C D E F G H R025inches (mm)5/8(15) 5 1/8(130)9 3/4(247) 2 13/16(72) 4 11/16(119)6(153)R050inches (mm)5/8(15) 6 3/4(171)11 7/8(301) 2 15/16(74) 4 11/16(119)6(153)R100inches (mm)7/8(22)9 1/8(232)14 7/8(378) 4 1/8(104) 4 15/16(126) 6 1/4(159)R200inches (mm)1 3/4(44)12 9/16(319)17 7/8(454)5 5/8(144)5 13/16(148)7 3/16(182)(1)For dimensions A and B, see fittings tables on pages 14–15.Dimensions continuedSensor with integrally mounted IFT9703 transmitterNPT female CAJON fitting dimensions5 3/4inches(mm) Dimensions inR0251 3/4 (45)1 15/16 (49)R025 1/2″–14 NPT female fittingR050 3/4″–14 NPT female fittingDimensions(1)Model C D E F K LR025inches(mm)5/8(15)5 1/8(130)9 3/4(247)2 13/16(72)7 13/16(199)14 1/16(358)R050inches(mm)5/8(15)6 3/4(171)11 7/8(301)2 15/16(74)7 13/16(199)15 11/16(398)R100inches(mm)7/8(22)9 1/8(232)14 7/8(378)4 1/8(104)8 1/16(205)18 5/16(466)R200inches(mm)1 3/4(44)12 9/16(319)17 7/8(454)5 5/8(144)8 15/16(228)22 5/8(575)(1)For dimensions A and B, see fittings tables on pages 14–15.12Micro Motion® R-Series FlowmeterMicro Motion ® R-Series Flowmeter 13Dimensions continuedSensor with core processorNPT female CAJON fitting dimensions″–14 NPT female fitting ″–14 NPT female fitting1 3/4(45)R0251 15/16(49)R050inches(mm)Dimensions in Dimensions (1)Model C D E F M N P Q R025inches (mm)5/8(15) 5 1/8(130)9 3/4(247) 2 13/16(72) 4 7/16(112) 2 11/16(69)9 13/16(249)8 1/16(205)R050inches (mm)5/8(15) 6 3/4(171)11 7/8(301) 2 15/16(74) 4 7/16(112) 2 11/16(69)9 13/16(249)8 1/16(205)R100inches (mm)7/8(22)9 1/8(232)14 7/8(378) 4 1/8(104) 4 11/16(119) 2 15/16(75)10 1/16(255)8 5/16(212)R200inches (mm)1 3/4(44)12 9/16(319)17 7/8(454)5 5/8(144)5 9/16(141)3 7/8(98)10 15/16(278)9 1/4(234)(1)For dimensions A and B, see fittings tables on pages 14–15.14Micro Motion ® R-Series FlowmeterFittings for R-Series flowmetersFitting codeDim. A face-to-face inches (mm)Dim B. outside diam.inches (mm)R025S fitting options (1)(1)Fittings listed here are standard options. Other types of fittings are available. Contact your local Micro Motion representative.1/2-inch ANSI 150 lb weld neck raised face flange 11316 (406) 3 1/2 (89)1/2-inch ANSI 300 lb weld neck raised face flange 11416 3/8 (416) 3 3/4 (95)1/2-inch ANSI 600 lb weld neck raised face flange 11516 7/8 (429) 3 3/4 (95)1/2-inch NPT female CAJON size 8 VCO fitting 31914 (356)(2)(2)Dimension specified in table does NOT include fitting length. For installation, modify Dim. A value to include fitting. See pages 11,12, and 13.not applicable 1/2-inch sanitary fitting (T ri-Clamp compatible)12114 (356) 1 (25)DN15 PN40 weld neck flange; DIN 2635 type C face11615 1/4 (387) 3 3/4 (95)DN15 PN100/160 weld neck flange; DIN 2638 type E face 12015 13/16 (401) 4 1/8 (105)JIS 15mm 10K/20K weld neck raised face flange 12215 7/16 (393) 3 3/4 (95)JIS 15mm 40K weld neck raised face flange 22116 1/2 (420) 4 1/2 (115)15mm DIN11851 aseptic coupling 22213 15/16 (353)Rd 34 × 1/8R050S fitting options (1)1/2-inch ANSI 150 lb weld neck raised face flange 11318 1/8 (460) 3 1/2 (89)1/2-inch ANSI 300 lb weld neck raised face flange 11418 1/2 (469) 3 3/4 (95)1/2-inch ANSI 600 lb weld neck raised face flange 11519 (482)3 3/4 (95)3/4-inch NPT female CAJON size 12 VCO fitting 23916 3/8 (415)(2)not applicable 3/4-inch sanitary fitting (T ri-Clamp compatible)32215 7/8 (403) 1 (25)DN15 PN40 weld neck flange; DIN 2635 type C face11617 3/8 (441) 3 3/4 (95)DN15 PN100/160 weld neck flange; DIN 2638 type E face 12017 7/8 (455) 4 1/8 (105)DN25 PN40 weld neck flange; DIN 2635 type C face 13117 1/2 (444) 4 1/2 (115)JIS 15mm 10K/20K weld neck raised face flange 12217 9/16 (446) 3 3/4 (95)JIS 15mm 40K weld neck raised face flange 22118 5/8 (473) 4 1/2 (115)15mm DIN11851 aseptic coupling 22216 (407)Rd 34 × 1/8R100S fitting options (1)1-inch ANSI 150 lb weld neck raised face flange 12822 11/16 (576) 4 1/4 (108)1-inch ANSI 300 lb weld neck raised face flange 12923 3/16 (588) 4 7/8 (124)1-inch ANSI 600 lb weld neck raised face flange 13023 11/16 (601) 4 7/8 (124)DN25 PN40 weld neck flange; DIN 2635 type C face13121 7/16 (544) 4 1/2 (115)DN25 PN100/160 weld neck flange; DIN 2638 type E face 13722 13/16 (580) 5 1/2 (140)1-inch sanitary fitting (T ri-Clamp compatible)13821 1/4 (540) 2 (50)JIS 25mm 10K/20K weld neck raised face flange 13921 11/16 (550) 4 15/16 (125)JIS 25mm 40K weld neck raised face flange 22922 15/16 (582) 5 1/8 (130)25mm DIN11851 aseptic coupling23020 9/16 (522)Rd 52 × 1/6Micro Motion ® R-Series Flowmeter 15Fittings for R-Series flowmeters continuedFittings for R-Series Model R025P high-pressure flowmeterFitting codeDim. A face-to-face inches (mm)Dim B. outside diam.inches (mm)R200S fitting options (1)(1)Fittings listed here are standard options. Other types of fittings are available. Contact your local Micro Motion representative.1 1/2-inch ANSI 150 lb weld neck raised face flange 34124 3/4 (629) 5 (127)1 1/2-inch ANSI 300 lb weld neck raised face flange 34225 1/4 (642) 6 1/8 (155)1 1/2-inch ANSI 600 lb weld neck raised face flange 34325 3/4 (654) 6 1/8 (155)2-inch ANSI 150 lb weld neck raised face flange 41824 7/8 (632) 6 (152)2-inch ANSI 300 lb weld neck raised face flange 41925 3/8 (645) 6 1/2 (165)2-inch ANSI 600 lb weld neck raised face flange 42026 1/8 (664) 6 1/2 (165)DN40 PN40 weld neck; DIN 2635 type C face 38123 9/16 (598) 5 15/16 (150)DN50 PN40 weld neck; DIN 2635 type C face 38223 5/8 (600) 6 1/2 (165)DN50 PN100 weld neck; DIN 2637 type E face 37825 1/4 (641)7 11/16 (195)DN50 PN160 weld neck; DIN 2638 type E face 37625 13/16 (655)7 11/16 (195)JIS 40mm 10K weld neck raised face flange 38523 7/16 (595) 5 1/2 (140)JIS 40mm 20K weld neck raised face flange 38723 7/16 (595) 5 1/2 (140)JIS 50mm 10K weld neck raised face flange 38623 7/16 (595) 6 1/8 (155)JIS 50mm 20K weld neck raised face flange 38823 5/8 (600) 6 1/8 (155)JIS 50mm 40K weld neck raised face flange 38925 7/16 (646) 6 1/2 (165)1 1/2-inch sanitary fitting (T ri-Clamp compatible)35123 1/4 (591) 2 (50)2-inch sanitary fitting (T ri-Clamp compatible)35222 7/8 (581) 2 1/2 (64)40mm DIN11851 aseptic coupling 35323 3/16 (589)Rd 65 × 1/650mm DIN11851 aseptic coupling35423 1/4 (591)Rd 78 × 1/6Fitting codeDim. A face-to-face inches (mm)Dim B. outside diam.inches (mm)15 mm DIN PN100/160 weld neck, DIN 2638, type E face 12015 13/16 (401) 4 1/8 (105)1/2-inch NPT female CAJON size 8 VCO fitting31914 (356)(1)(1)Dimension specified in table does NOT include fitting length. For installation, modify Dim. A value to include fitting. See pages 11,12, and 13.not applicable16Micro Motion ® R-Series FlowmeterOrdering informationStandard sensor modelsR025S R-Series sensor; 1/4-inch; 316L stainless steel R050S R-Series sensor; 1/2-inch; 316L stainless steel R100S R-Series sensor; 1-inch; 316L stainless steel R200SR-Series sensor; 2-inch; 316L stainless steel High-pressure modelsR025P R-Series sensor; 1/4-inch; 316L stainless steel; 2300 psi tube rating ###See fittings option tables on pages 14–15N Standard case Q 4-wire epoxy-painted aluminum integral core processor for remotely mounted transmitter with MVD Technology A 4-wire stainless steel integral core processor for remotely mounted transmitter with MVD TechnologyV 4-wire epoxy-painted aluminum integral core processor with extended mount for remotely mounted transmitter with MVD TechnologyB 4-wire stainless steel integral core processor with extended mount for remotely mounted transmitter with MVD TechnologyC Integrally mounted Model 1700 (all output options) or Model 2700 (F OUNDATION fieldbus or Profibus-PA) transmitter W(1)(1)When electronics interface W, D, Y , or E is ordered with approval C, A, or Z, an MVD Direct Connect I.S. barrier is supplied.No barrier is supplied when ordered with approval codes M or N.MVD Solo; epoxy-painted aluminum integral core processor for direct host communication D (1)MVD Solo; stainless steel integral core processor for direct host communicationY (1)MVD Solo; epoxy-painted aluminum integral core processor with extended mount for direct host communication E (1)MVD Solo; stainless steel integral core processor with extended mount for direct host communication I Integrally mounted IFT9703 transmitter Electronics interface codes Q, A, V, B, W, D, Y, and E (integral core processor)B 1/2-inch NPT — no gland E M20 — no glandF Brass/nickel cable gland (cable diameter 8.5 to 10 mm)GStainless steel cable gland (cable diameter 8.5 to 10 mm)Electronics interface codes C or I (integrally mounted transmitter)A No glandContinued on next pageOrdering information continuedM Micro Motion standard — no approvalN Micro Motion standard / PED compliantC CSA (Canada only)A CSA (U.S.A. and Canada) — not available with electronics interface code IU UL—only available with electronics interface code IZ ATEX — Equipment category 2 (Zone 1) / PED compliantA Danish quick reference and English manualD Dutch quick reference and English manualE English quick reference and English manualF French quick reference and French manualG German quick reference and German manualH Finnish quick reference and English manualI Italian quick reference and English manualJ Japanese quick reference and English manualM Chinese quick reference and English manualN Norwegian quick reference and English manualO Polish quick reference and English manualP Portuguese quick reference and English manualR Russian quick reference and English manualS Spanish quick reference and Spanish manualW Swedish quick reference and English manualZ Reserved for future useZ Reserved for future useZ Reserved for future useZ Standard productX CEQ productR Restocked product (if available)Micro Motion® R-Series Flowmeter1718Micro Motion® R-Series FlowmeterMicro Motion® R-Series Flowmeter19©2004, Micro Motion, Inc. All rights reserved. P/N PS-00363, Rev. BDue to Micro Motion’s commitment to continuous improvement of our products, all specifications are subject to change without notice. Micro Motion is a registered trademark of Micro Motion, Inc. The Micro Motion and Emerson logos are trademarks of Emerson Electric Co. All other trademarks are property of their respective owners.Micro Motion Inc. USAWorldwide Headquarters7070 Winchester CircleBoulder, Colorado 80301T(303) 530-8400(800) 522-6277F(303) 530-8459Micro Motion EuropeEmerson Process ManagementWiltonstraat 303905 KW VeenendaalThe NetherlandsT+31 (0) 318 495 670F+31 (0) 318 495 689Micro Motion United Kingdom Emerson Process Management Limited Horsfield WayBredbury Industrial EstateStockport SK6 2SU U.K.T0800 966 180F0800 966 181Micro Motion Japan Emerson Process Management Shinagawa NF Bldg. 5F1-2-5, Higashi Shinagawa Shinagawa-kuTokyo 140-0002 JapanT(81) 3 5769-6803F(81) 3 5769-6843Micro Motion AsiaEmerson Process Management 1 Pandan Crescent Singapore 128461Republic of SingaporeT(65) 6777-8211F(65) 6770-8003Micro Motion。

Perkadox 16产品数据表说明书

Product Data SheetPerkadox 16Di(4-tert-butylcyclohexyl) peroxydicarbonatePerkadox® 16 is applied as an initiator for the suspension and mass polymerization of vinyl chloride in the temperature range between 40°C and 65°C. Perkadox® 16 can be used alone or in combination with other peroxides, such as 1,1,3,3-Tetramethylbutyl peroxyneodecanoate (Trigonox 423), Cumyl peroxyneodecanoate (Trigonox 99) or Dilauroyl peroxide (Laurox), to increase reactor efficiency.CAS number15520-11-3EINECS/ELINCS No.239-557-1TSCA statuslisted on inventoryMolecular weight398.5SpecificationsAppearance White powderAssay94.0-97.0 %Inorganic + organic hydrolysable chloride≤ 4000 mg/kgCharacteristicsBulk density, 20 °C450-480 kg/m³Density, 20 °C 1.13 g/cm³ApplicationsPerkadox® 16 can be used for the market segments: polymer production, thermoset composites and acrylics with their different applications/functions. For more information please check our website and/or contact us.Half-life dataThe reactivity of an organic peroxide is usually given by its half-life (t½) at various temperatures. For Perkadox® 16 in chlorobenzene:0.1 hr82°C (180°F)1 hr64°C (147°F)10 hr48°C (118°F)Formula 1kd = A·e-Ea/RTFormula 2t½ = (ln2)/kdEa126.39 kJ/moleA7.44E+15 s-1R8.3142 J/mole·KT(273.15+°C) KThermal stabilityOrganic peroxides are thermally unstable substances, which may undergo self-accelerating decomposition. The lowest temperature at which self-accelerating decomposition of a substance in the original packaging may occur is the Self-Accelerating Decomposition Temperature (SADT). The SADT is determined on the basis of the Heat Accumulation Storage Test.SADT40°CEmergency temperature (Tₑ)35°CControl temperature (Tc)30°CMethod The Heat Accumulation Storage Test is a recognized test method for thedetermination of the SADT of organic peroxides (see Recommendations on theTransport of Dangerous Goods, Manual of Tests and Criteria – United Nations,New York and Geneva).StorageDue to the relatively unstable nature of organic peroxides a loss of quality can be detected over a period of time. To minimize the loss of quality, Nouryon recommends a maximum storage temperature (Ts max. ) for each organic peroxide product.Ts max.20°C (please see note below)Note When stored under the recommended storage conditions, Perkadox® 16 willremain within the Nouryon specifications for a period of at least 3 months afterdelivery. The Ts max of 20°C is not to be interpretated as ambient or roomtemperature as this differs per region and season. Perkadox® 16 has a high qualitycomposition and to hold that it should be stored at below 20°C. At temperaturesabove 20°C the decomposition of Perkadox® 16 progresses fast which leads tosignificant loss of quality. If you have questions about this, please contact yourlocal Nouryon account manager for advice.Packaging and transportIn North America Perkadox® 16 is packed in non-returnable cartons containing 25 polyethylene bags of 1 lb net weightor 5 polyethylene bags of 5 lb net weight. In other regions the standard packaging is a cardboard box for 20 kg peroxide. Both packaging and transport meet the international regulations. For the availability of other packed quantities contact your Nouryon representative. Perkadox® 16 is classified as Organic peroxide type C; solid, temperature controlled; Division 5. 2; UN 3114.Safety and handlingKeep containers tightly closed. Store and handle Perkadox® 16 in a dry well-ventilated place away from sources of heat or ignition and direct sunlight. Never weigh out in the storage room. Avoid contact with reducing agents (e. g. amines), acids, alkalis and heavy metal compounds (e. g. accelerators, driers and metal soaps). Please refer to the Safety Data Sheet (SDS) for further information on the safe storage, use and handling of Perkadox® 16. This information should be thoroughly reviewed prior to acceptance of this product. The SDS is available at /sds-search.Major decomposition products Carbon dioxide, 4-tert-Butyl-cyclohexanolAll information concerning this product and/or suggestions for handling and use contained herein are offered in good faith and are believed to be reliable.Nouryon, however, makes no warranty as to accuracy and/or sufficiency of such information and/or suggestions, as to the product's merchantability or fitness for any particular purpose, or that any suggested use will not infringe any patent. Nouryon does not accept any liability whatsoever arising out of the use of or reliance on this information, or out of the use or the performance of the product. Nothing contained herein shall be construed as granting or extending any license under any patent. Customer must determine for himself, by preliminary tests or otherwise, the suitability of this product for his purposes.The information contained herein supersedes all previously issued information on the subject matter covered. The customer may forward, distribute, and/or photocopy this document only if unaltered and complete, including all of its headers and footers, and should refrain from any unauthorized use. Don’t copythis document to a website.Perkadox® and Trigonox are registered trademarks of Nouryon Functional Chemicals B.V. or affiliates in one or more territories.Contact UsPolymer Specialties Americas************************Polymer Specialties Europe, Middle East, India and Africa*************************Polymer Specialties Asia Pacific************************2023-1-10© 2023Polymer production Perkadox 16。

电磁炉系列产品说明书

Serie 8, Placa de inducción, 80 cm, NegroPIE875DC1EHEZ390090 Wok para radiantes e inducciónHEZ390210 Sartén antiadherente de 15 cm. de base. HEZ390220 Sartén antiadherente de 19 cm de base HEZ390230 Sartén antiadherente de 21 cm de base HEZ390250 Sartén antiadherente de 28 cm de base HEZ394301 Accesorio de uniónHEZ9ES100 Cafetera 4 tazasHEZ9FE280 Sartén de hierro Ø 18 / 28 cmHEZ9SE030 Set de 2 ollas y 1 sarténHEZ9SE040 set de 4 piezasHEZ9SE060 set de 6 piezas Encimera de inducción con PerfectFry: logra resultados de fritura perfectos gracias al control automático de temperatura.• DirectSelect Premium: selección directa y fácil de la zona decocción, potencia y funciones deseada.• PerfectFry: Un perfecto dorado al momento de freír gracias al sensor de control con 5 niveles de potencia.• PowerBoost: hasta un 50% más de potencia para una cocción más rápida.• QuickStart: start comience de inmediato a cocinar y seleccione el nivel de cocción deseado.• ReStart: si algo se derrama, la placa de cocción se apagaautomáticamente y guarda la última configuración seleccionada.Familia de Producto: ..........................Placa independie.vitrocerámica Tipo de construcción: .........................................................Integrable Entrada energética: ...............................................................Eléctrico Número de posiciones que se pueden usar al mismo tiempo: . (4)Medidas del nicho de encastre: ...............51 x 750-780 x 490-500 mm Anchura: .................................................................................816 mm Dimensiones aparato (alto, ancho, fondo): ...........51 x 816 x 527 mm Medidas del producto embalado: ........................126 x 953 x 603 mm Peso neto: ...............................................................................13.3 kg Peso bruto: ..............................................................................17.0 kg Indicador de calor residual: .................................................Separado Ubicación del panel de mandos: ...............Frontal de la vitrocerámica Material de la superficie básica: ....................................Vitrocerámica Color de superficie superior: ........................Negro, Aluminio gratado Longitud del cable de alimentación eléctrica: ......................110.0 cm Sealed Burners: ..............................................................................No Zonas con booster: ....................................................................Todas Potencia del elemento calentador: ...........................................2.2 kW Potencia del tercer elemento calentador: ................................1.4 kW Potencia del quinto elemento calentador: ...............................2.6 kW Power of heating element (kW in boost): ..............................[3.7] kW Power of 3rd heating element (kW in boost): ........................[2.1] kW Power of 5th heating element (kW in boost): ........................[3.7] kW Potencia: .................................................................................7400 W Tensión: ..............................................................................220-240 V Frecuencia: ..........................................................................60; 50 Hz Entrada energética: ...............................................................Eléctrico Tipo de clavija: ..................................................................sin enchufe Appliance Dimensions (h x w x d) (in): ..........................................x x Dimensions of the packed product: ....................4.96 x 23.74 x 37.51 Net weight: .........................................................................29.000 lbs Gross weight: .....................................................................37.000 lbs Número de posiciones que se pueden usar al mismo tiempo: . (4)Longitud del cable de alimentación eléctrica: ......................110.0 cm Medidas del nicho de encastre: ...............51 x 750-780 x 490-500 mm Dimensiones aparato (alto, ancho, fondo): ...........51 x 816 x 527 mm Medidas del producto embalado: ........................126 x 953 x 603 mm Peso neto: ...............................................................................13.3 kg Peso bruto: ..............................................................................17.0 kgSerie 8, Placa de inducción, 80 cm, NegroPIE875DC1EEncimera de inducción con PerfectFry: logra resultados de fritura perfectos gracias al control automático de temperatura.Diseño:- Combinación perfecta con el resto de placas de cristal vitrocerámico y terminación PremiumConfort:- 4 zonas de inducción- Programación de tiempo de cocción para cada zona y avisador acústico- Avisador acústico- STFE- Regulación electrónica con 17 niveles de potencia- Detección de recipiente- Posibilidad de limitar la potencia total de la encimera- Desconexión de seguridad de la placa- Bloqueo de seguridad para niños automático o manual- Función Clean: bloqueo temporal del control- Display de consumo de energía- Función Sprint en todas las zonasSeguridad:- Indicador de calor residual dual (H/h)- Main Switch- Sensor PerfectFry con 5 ajustes de temperaturaSerie 8, Placa de inducción, 80 cm,NegroPIE875DC1E。

Incucyte

Product Information Presentation, Storage and StabilityThe Incucyte® Fabfluor-pH Antibody Labeling Reagents for antibody internalization are supplied as lyophilized solids in sufficient quantity to label 50 μg of test antibody, when used at the suggested molar ratio (1:3 of test antibody to labeling Fab). The lyophilized solid can be stored at 2-8° C for one year. Once re-hydrated, any unused reagent should be aliquoted and stored at -80° C for up to one year. Avoid repeated freeze-thaw cycles.Incucyte® Fabfluor-pH Antibody Labeling ReagentsFor Antibody Internalization AssaysAntibody Labeling Reagent Rehydrated: -80° C *Excitation and Emission maxima were determined at a pH of 4.5.Fabfluor_quick_guideBackgroundIncucyte ® Fabfluor-pH Antibody Labeling Reagents are designed for quick, easy labeling of Fc-containing test antibodies with a Fab fragment-conjugated pH-sensitive fluorophore. The pH-sensitive dye based system exploits the acidic environment of the lysosomes to quantify in-ternalization of the labeled antibody. As Fabfluor labeled antibodies reside in the neutral extracellular solution (pH 7.4), they interact with cell surface specific antigens and are internalized. Once in the lysosomes, they enter an acidic environment (pH 4.5–5.5) and a substantial in-crease in fluorescence is observed. In the absence of ex-pression of the specific antigen, no internalization occurs and the fluorescence intensity of the labeled antibodies remains low. With the Incucyte ® integrated analysis soft-ware, background fluorescence is minimized. These reagents have been validated for use with a number of different antibodies in a range of cell types. The Incucyte ® Live-Cell Analysis System enables real-time, kinetic eval -uation of antibody internalization.Recommended UseWe recommend that the Incucyte ® Fabfluor-pH Antibody Labeling Reagents are prepared at a stock concentration of 0.5 mg/mL by the addition of 100 μL of sterile water and triturated (centrifuge if solution not clear). The reagent may then be diluted directly into the labeling mixture with test antibody. Do NOT sonicate the solution.Additional InformationThe Fab antibody was purified from antisera by a combination of papain digestion and immunoaffinity chromatography using antigens coupled to agarose beads. Fc fragments and whole IgG molecules have been removed.Human Red (Cat. No. 4722) or Human Orange (Cat. No. 4812)—Based on immunoelectrophoresis and/ or ELISA, the antibody reacts with the Fc portion of human IgG heavy chain but not the Fab portion of human IgG. No antibody was detected against human IgM, IgA or against non-immunoglobulin serum proteins. The anti-body may cross-react with other immunoglobulins from other species.Mouse IgG1 (Cat. No. 4723), IgG2a (Cat. No. 4750) or IgG2b (Cat. No. 4751)—Based on antigen-binding assay and/or ELISA, the antibody reacts with the Fc portion of mouse IgG, IgG2a or IgG2b, respectively, but not the Fab portion of mouse immunoglobulins. No antibody was detected against mouse IgM or against non–immunoglobulin serum proteins. The antibody may cross-react with other mouse IgG subclasses or with immunoglobulins from other species.Rat (Cat. No. 4737)—Based on immunoelectrophoresis and/or ELISA, the antibody reacts with the Fc portion of rat IgG heavy chain but not the Fab portion of rat IgG. No antibody was detected against rat IgM, IgA or against non-immunoglobulin serum proteins. The antibody may cross-react with other immunoglobulins from other species.A.B.C.D.R e d O b j e c t A r e a (x 105 μm 2 p e r w e l l )Time (hours)A U C x 106 (0–12 h )log [α–CD71] (g/mL)Example DataFigure 1: Concentration-dependent increase in antibody internalization of Incucyte ® Fabfluor labeled-α-CD71 in HT1080 cells. α-CD71 and mouse IgG1 isotype control were labeled with Incucyte ® Mouse IgG1 Fabfluor-pH Red Antibody Labeling Reagent. HT1080 cells were treated with either Fabfluor-α-CD71 or Fabfluor-IgG1 (4 μg/mL); HD phase and red fluorescence images were captured every 30 minutes over 12 hours using a 10X magnification. (A) Images of cells treated with Fabfluor-α-CD71 display red fluorescence in the cytoplasm (images shown at 6 h). (B) Cells treated with labeled isotype control display no cellular fluorescence. (C) Time-course of Fabfluor-α-CD71 internalization with increasing concentrations of Fabfluor-α-CD71 (progressively darker symbols). Internalization has been quantified as the red object area for each time-point. (D) Concentration response curve to Fabfluor-α-CD71. Area under the curve (AUC) values have been determined from the time-course shown in panel C (0-12 hours) and are presented as the mean ± SEM, n=3 wells.CD71-FabfluorIgG-FabfluorProtocols and ProceduresMaterialsIncucyte® Fabfluor-pH Antibody Labeling ReagentTest antibody of interest containing human, mouse, or rat IgG Fc region (at known concentration)Target cells of interestTarget cell growth mediaSterile distilled water96-well flat bottom microplate (e.g. Corning Cat. No. 3595) for imaging96-well round black round bottom ULA plate (e.g. Corning Cat. No. 45913799) or amber microtube (e.g. Cole Parmer Cat. No. MCT-150-X, autoclaved) for conjugation step0.01% Poly-L-Ornithine (PLO) solution (e.g. Sigma Cat. No. P4957), optional for non-adherent cells Recommended control antibodiesIt is strongly recommended that a positive and negative control is run alongside test antibodies and cell lines. For example, CD71, which is a mouse anti-human antibody, is recommended as a positive control for the mouse Fab.Anti-CD71, clone MEM-189, IgG1 e.g. Sigma Cat. No. SAB4700520-100UGAnti-CD71, clone CYG4, IgG2a e.g. BioLegend Cat. No. 334102Isotype controls, depending on isotype being studied—Mouse IgG1, e.g. BioLegend Cat. No. 400124, Mouse IgG2a e.g. BioLegend Cat. No. 401501Preparation of Incucyte® Antibody Internalization Assay 1. Seed target cells of interest1.1 Harvest cells of interest and determine cell concentra-tion (e.g. trypan blue + hemocytometer).1.2 Prepare cell seeding stock in target cell growth mediawith a cell density to achieve 40–50% confluence be-fore the addition of labeled antibodies. The suggested starting range is 5,000–30,000 cells/well, although the seeding density will need to be optimized for each cell type.Note: For non-adherent cell types, a well coating may be required to maintain even cell distribution in the well. For a 96-well flat bottom plate, we recommend coating with 50 μL of either 0.01% Poly-L-Or-nithine (PLO) solution or 5 μg/mL fibronectin diluted in 0.1% BSA.Coat plates for 1 hour at ambient temperature, remove solution from wells and then allow the plates to dry for 30-60 minutes prior to cell addition.1.3 Using a multi-channel pipette, seed cells (50 µL perwell) into a 96-well flat bottom microplate. Lightly tapplate side to ensure even liquid distribution in well. Toensure uniform distribution of cells in each well, allowthe covered plate sit on a level surface undisturbed at room temperature in the tissue culture hood for 30minutes. After cells are settled, place the plate insidethe Incucyte® Live-Cell Analysis System to monitor cell confluence.Note: Depending on cell type, plates can be used in assay once cells have adhered to plastic and achieved normal cell morphology e.g.2-3 hours for HT1080 or 1-2 hours for non-adherent cell types. Some cell types may require overnight incubation.2. Label Test Antibody2.1 Rehydrate the Incucyte® Fabfluor-pH Antibody Label-ing Reagent with 100 µL sterile water to result in a final concentration of 0.5 mg/mL. Triturate to mix (centrifuge if solution is not clear).Note: The reagent is light sensitive and should be protected fromlight. Rehydrated reagent can be aliquoted into amber or foilwrapped tubes and stored at -80° C for up to 1 year (avoid freezing and thawing).2.2 Mix test antibody with rehydrated Incucyte® Fabfluor–pH Antibody Labeling Reagent and target cell growth media in a black round bottom microplate or ambertube to protect from light (50 µL/well).a. Add test antibody and Incucyte® Fabfluor–pH Anti-body Labeling Reagent at 2X the final concentration.We suggest optimizing the assay by starting with afinal concentration of 4 µg/mL of test antibody or theFabfluor-pH Antibody Labeling Reagent (i.e. 2Xworking concentration = 8 µg/mL).Note: A 1:3 molar ratio of test antibody to Incucyte® Fabfluor-pHAntibody Labeling Reagent is recommended. The labeling re-agent is a third of the size of a standard antibody (50 and 150KDa, respectively). Therefore, labeling equal quantities will pro-duce a 1:3 molar ratio of test antibody to labeling Fab.b. Make sufficient volume of 2X labeling solution for50 µL/well for each sample. Triturate to mix.c. Incubate at 37° C for 15 minutes protected from light.Note: If performing a range of concentrations of test antibody,e.g. concentration response-curve, it is recommended to createthe dilution series post the conjugation step to ensure consistentmolar ratio. We strongly recommend the use of both a negativeand positive control antibody in the same plate.3. Add labeled antibody to cells3.1 Remove cell plate from incubator.3.2 Using a multi-channel pipette, add 50 µL of 2X labeledantibody and control solutions to designated wells.Remove any bubbles and immediately place plate in the Incucyte® Live-Cell Analysis System and start scanning.Note: To reduce the risk of condensation formation on the lid priorto first image acquisition, maintain all reagents at 37° C prior toplate addition.4. Acquire images and analyze4.1 In the Incucyte® Software, schedule to image every15-30 minutes, depending on the speed of the specific antibody internalization.a Scan on schedule, standard. If the Incucyte® Cell-by-Cell Analysis Software Module (Cat. No. 9600-0031)is available, adherent cell-by-cell or non-adherentcell-by-cell scan types can be selected.b Channel selection: select “phase” and “red” or“phase” and "orange” (depending on reagent used).c Objective: 10X or 20X depending on cell types used,generally 10X is recommended for adherent cells,and 20X for non-adherent or smaller cells.NOTE: The optional Incucyte® Cell-by-Cell Analysis SoftwareModule enables the classification of cells into sub-populationsbased on properties including fluorescence intensity, size andshape. For further details on this analysis module and its appli-cation, please see: /cell-by-cell.4.2 To generate the metrics, user must create an AnalysisDefinition suited to the cell type, assay conditions andmagnification selected.4.3 Select images from a well containing a positiveinternalization signal and an isotype control well(negative signal) at a time point where internalizationis visible.4.4 In the Analysis Definition:Basic Analyzer:a. Set up the mask for the phase confluence measurewith fluorescence channel turned off.b. Once the phase mask is determined, turn the fluores-cence channel on: Exclude background fluorescencefrom the mask using the background subtractionfeature. The feature “Top-Hat” will subtract localbackground from brightly fluorescent objects withina given radius; this is a useful tool for analyzing ob-jects which change in fluorescence intensity overtime.i The radius chosen should reflect the size of thefluorescent object but contain enough backgroundto reliably estimate background fluorescence inthe image; 20-30 μm is often a useful startingpoint.ii The threshold chosen will ensure that objectsbelow a fluorescence threshold will not bemasked.iii Choose a threshold in which red or orange objectsare masked in the positive response image but lownumbers in the isotype control, negative responsewell. For a very sensitive measurement, for example,if interested in early responses, we suggest athreshold of 0.2.NOTE: The Adaptive feature can be used for analysis but maynot be as sensitive and may miss early responses. If interestedin rate of response, Top-Hat may be preferable.Cell-by-Cell (if available):a. Create a Cell-by-Cell mask following the softwaremanual.b. There is no need to separate phase and fluorescencemasks. The default setting of Top-Hat No Mask forthe fluorescence channel will enable backgroundsubtraction without generation of a mask. Ensurethat the Top-Hat radius is set to a value higher thanthe radius of the larger clusters to avoid excess back-ground subtraction.c. The threshold of fluorescence can be determined inCell-by-Cell Classification.Specifications subject to change without notice.© 2020. All rights reserved. Incucyte, Essen BioScience, and all names of Essen BioScience prod -ucts are registered trademarks and the property of Essen BioScience unless otherwise specified. Essen BioScience is a Sartorius Company. Publication No.: 8000-0728-A00Version 1 | 2020 | 04Sales and Service ContactsFor further contacts, visit Essen BioScience, A Sartorius Company /incucyte Sartorius Lab Instruments GmbH & Co. KGOtto-Brenner-Strasse 20 37079 Goettingen, Germany Phone +49 551 308 0North AmericaEssen BioScience Inc. 300 West Morgan Road Ann Arbor, Michigan, 48108USATelephone +1 734 769 1600E-Mail:***************************EuropeEssen BioScience Ltd.Units 2 & 3 The Quadrant Newark CloseRoyston Hertfordshire SG8 5HLUnited KingdomTelephone +44 (0) 1763 227400E-Mail:***************************APACEssen BioScience K.K.4th floor Daiwa Shinagawa North Bldg.1-8-11 Kita-Shinagawa Shinagawa-ku, Tokyo 140-0001 JapanTelephone: +81 3 6478 5202E-Mail:*************************5. Analysis GuidelinesAs the labeled antibody is internalized into the acidic environment of the lysosome, the area of fluorescence intensity inside the cells increases.This can be reported in two ways:Ways to Report Basic AnalyzerCell-by-Cell Analysis* To correct for cell proliferation, it is advisable to normalize the fluorescence area to the total cell area using User Defined Metrics.For Research Use Only. Not For Therapeutic or Diagnostic Use.LicensesFor non-commercial research use only. Not for therapeutic or in vivo applications. Other license needs contact Essen BioS cience.Fabfluor-pH Red Antibody Labeling Reagent: This product or portions thereof is manufactured under license from Carnegie Mellon University and U.S. patent numbers 7615646 and 8044203 and related patents. This product is licensed for sale only for research. It is not licensed for any other use. There is no implied license hereunder for any commercial use.Fabfluor-pH Orange Antibody Labeling Reagent: This product or portions thereof is manufactured under a license from Tokyo University and is covered by issued patents EP2098529B1, JP5636080B2, US8258171, and US9784732 and related patent applications. This product and related products are trademarks of Goryo Chemical. Any application of above mentioned technology for commercial purpose requires a separate li -cense from: Goryo Chemical, EAREE Bldg., SF Kita 8 Nishi 18-35-100, Chuo-Ku, Sapporo, 060-0008 Japan.SupportA complete suite of cell health applications is available to fit your experimental needs. Find more information at /incucyte Foradditionalproductortechnicalinformation,************************************************************/incucyte。

中科院SCI分区目录

批注本地保存成功开通会员云端永久保存去开通
刊名简称 J AM CHEM SOC ANGEW CHEM INT EDIT ANAL CHEM CHEM REV ACCOUNTS CHEM RES COORDIN CHEM REV CHEM SOC REV ANNU REV PHYS CHEM PROG POLYM SCI TOP CURR CHEM ADV POLYM SCI SURF SCI REP CATAL REV CURR OPIN COLLOID IN ADV CATAL ADV ORGANOMET CHEM PROG SOLID STATE CH ALDRICHIM ACTA J ORG CHEM MACROMOLECULES CHEM COMMUN INORG CHEM J PHYS CHEM B LANGMUIR J CHROMATOGR A ORGANOMETALLICS DALTON T J CATAL ORG LETT CHEM-EUR J ELECTROPHORESIS J COMPUT CHEM CARBON RAPID COMMUN MASS SP CHEM RES TOXICOL J ANAL ATOM SPECTROM APPL CATAL B-ENVIRON MACROMOL RAPID COMM J AM SOC MASS SPECTR J PHYS CHEM REF DATA FARADAY DISCUSS J MASS SPECTROM ADV COLLOID INTERFAC BIOMACROMOLECULES TRAC-TREND ANAL CHEM ELECTROCHEM COMMUN J BIOL INORG CHEM ADV SYNTH CATAL ADV INORG CHEM CHEMPHYSCHEM GREEN CHEM J COMB CHEM PROG SURF SCI CRYST GROWTH DES

荷尔登生物医学检测产品说明书

1mL
R
1mL
SST, R, GL
1mL
No capillary
1mL
collection
Order of Draw: 1. BLOOD CULTURES 2. LT BLUE 3. RED 4. SST 5. PST/LH GRN 6. LAV 7. GRAY
M2909 (1-19)
Microtainer Microtainer 1 mL
2 Microtainers Microtainer
2 mL FILL TO LINE 1 mL 1 mL Microtainer 1 mL 1 mL Microtainer
SST, R, GL
STAT to lab in 10 min
Also known as CMP SST, R, GL SST, R, GL
TOBRAMYCIN TOTAL PROTEIN TROPONIN TSH
TYPE AND CROSSMATCH
TYPE AND SCREEN URIC ACID
VANCOMYCIN VALPROIC ACID VITAMIN D
FEA
6LA LHC 6LIP
6LIVER 6LIPID LIA 6MG 6METX 6MONO PHNOC 6PFA 6PHOS 6PBNP 6PCAL 6KA 6PTIMEN PSAC 6PTT 6RETCT 6RENAL WHRIG 6SAL SYPHB TBSATA TT3C T4C TESTOC THEOC
CHEM8
QUICK CHEM 8 CBC/AUTO DIFF CKMB
COMP CREATININE CREATININE X-RAY EVALUATION D-DIMER DIGOXIN DILANTIN ELECTROLYTES FERRITIN FSH GLUCOSE

Artemether (SM-224) 71963-77-4 GlpBio

Peptides, Inhibitors, AgonistsProduct Data SheetProduct Name: Artemether (SM-224)Cat. No.:GC12784Chemical Name: (3R,5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromeneCHEMICAL PROPERTIESCas No.: 71963-77-4Molecular Formula: C16H26O5Molecular Weight: 298.4Storage: PowderSolubility: >15.3mg/mL in DMSOChemical Structure:BackgroundArtemether is a semi-synthetic derivative of artemisinin (qinghaosu), a naturally occurring peroxide lactone derived from a traditional Chinese herbal remedy Artemisia annua L., to enhance the solubility and antimalarial activity of its parental compound. Artemether exhibits potent antimalarial and antischistosomal activities against malarial parasites and Schistosoma japonicum infections. Although it has not been well elucidated, an endoperoxide bridge within the chemical structure of Artemether might be the key characteristic considered to be responsible for its antimalarial and antischistosomal activities, which can be metabolized by malarial or schistosomal parasites, under in vivo conditions, generating detrimental oxygen radicals to attack parasite macromolecules.Research Update1. Effect of Hydrofluoric Acid Concentration and Etching Time on Bond Strength to Lithium Disilicate Glass Ceramic. Oper Dent. 2017 Nov/Dec;42(6):606-615. doi: 10.2341/16-215-L. Epub 2017 Jul 14. PMID:28708007AbstractThe aim of this study was to evaluate the influence of different concentrations of hydrofluoric acid (HF) associated with varied etching times on the microshear bond strength (μSBS) of a resin cement to a lithium disilicate glass ceramic. Two hundred seventy-fiveceramic blocks (IPS e.max Press [EMX], Ivoclar Vivadent), measuring 8 mm × 3 mm thickness, were randomly distributed into fiv e groups according to the HF concentrations (n=50): 1%, 2.5%, 5%, 7.5%, and 10%.2. Does acid etching morphologically and chemically affect lithium disilicate glass ceramic surfaces? J Appl Biomater Funct Mater. 2017 Jan 26;15(1):e93-e100. doi: 10.5301/jabfm.5000303. PMID:27647389AbstractBACKGROUND: This study evaluated the surface morphology, chemical composition and adhesiveness of lithium disilicate glass ceramic after acid etching with hydrofluoric acid or phosphoric acid.METHODS: Lithium disilicate glass ceramic specimens polished by 600-grit silicon carbide paper were subjected to one or a combination of these surface treatments: airborne particle abrasion with 50-μm alumina (AA), etching with 5% hydrofluoric acid (HF) or 36% phosphoric acid (Phos), and application of silane co upling agent (Si).3. Fatigue failure load of feldspathic ceramic crowns after hydrofluoric acid etching at different concentrations. J Prosthet Dent. 2018 Feb;119(2):278-285. doi: 10.1016/j.prosdent.2017.03.021. Epub 2017 May 26. PMID:28552291AbstractSTATEMENT OF PROBLEM: Hydrofluoric acid etching modifies the cementation surface of ceramic restorations, which is the same surface where failure is initiated. Information regarding the influence of hydrofluoric acid etching on the cyclic loads to failure of ceramic crowns is lacking.PURPOSE: The purpose of this in vitro study was to evaluate the influence of different hydrofluoric acid concentrations on the fatigue failure loads of feldspathic ceramic crowns.。

1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。

Product Name:
Artemether CAS No.:
71963-77-4Cat. No.:
HY-N0402Product Data Sheet
MWt:
298.37Formula:
C16H26O5Purity :>98%
DMSO 60 mg/mL; Water <1 mg/mL Solubility:Mechanisms:
Biological Activity:
A t th i ti l i l f th t t t f i t t t i f f l i l i
Pathways:Anti-infection; Target:Antiparasitic SO 60g/;ate g/
Artemether is an antimalarial for the treatment of resistant strains of falciparum malaria.
Target: Antiparasitic Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. Artemether exhibits the highest activity against juvenile stages of the parasites, while adult worms are significantly less susceptible. There was no indication of neurotoxicity following repeated high doses of artemether given fortnightly for up to 5months. Artemether-integrated with other control strategies-has considerable potential for reducing the current burden of schistosomiasis in different epidemiological settings [1]. There were
remarkably inhibitory effects of artmeter on brain glioma growth and angiogenesis in SD rats and the References:
[1]. Xiao, S., et al., Recent investigations of artemether, a novel agent for the prevention of
schistosomiasis japonica, mansoni and haematobia. Acta Trop, 2002. 82(2): p. 175-81.[2]. Wu, Z.P., et al., Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6
remarkably inhibitory effects of artmeter on brain glioma growth and angiogenesis in SD rats and the mechanism that artemether inhibited brain glioma growth might be pen...
orthotopic brain gliomas model. Integr Cancer Ther, 2009. 8(1): p. 88-92.Caution: Not fully tested. For research purposes only
Medchemexpress LLC
18W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S A
E m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m。